UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549
FORM 10-Q
(Mark One)
| x | Quarterly Report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 |
For the quarterly period ended December 31, 2007
or
| ¨ | Transition Report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 |
For the transition period from to
Commission File No. 000-16723
RESPIRONICS, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 25-1304989 | |
|
(State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification Number) |
|
1010 Murry Ridge Lane Murrysville, Pennsylvania |
15668-8525 | |
| (Address of principal executive offices) | (Zip Code) |
724-387-5200
(Registrants Telephone Number, including area code)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨ .
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of accelerated filer and large accelerated filer in Rule 12b-2 of the Exchange Act (Check One):
Large accelerated filer x Accelerated filer ¨ Non-accelerated filer ¨
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x
As of January 31, 2008, there were 81,336,625 shares of Common Stock of the registrant issued, of which 74,346,330 were outstanding, and 6,990,295 were held in treasury.
RESPIRONICS, INC.
2
| Item 1. | Financial Statements |
Report of Independent Registered Public Accounting Firm
Board of Directors
Respironics, Inc. and Subsidiaries
We have reviewed the consolidated balance sheet of Respironics, Inc. and Subsidiaries (the Company) as of December 31, 2007, and the related consolidated statements of operations for the three-month and six-month periods ended December 31, 2007 and 2006, and the condensed consolidated statements of cash flows for the six-month periods ended December 31, 2007 and 2006. These financial statements are the responsibility of the Companys management.
We conducted our review in accordance with the standards of the Public Company Accounting Oversight Board (United States). A review of interim financial information consists principally of applying analytical procedures and making inquiries of persons responsible for financial and accounting matters. It is substantially less in scope than an audit conducted in accordance with the standards of the Public Company Accounting Oversight Board, the objective of which is the expression of an opinion regarding the financial statements taken as a whole. Accordingly, we do not express such an opinion.
Based on our review, we are not aware of any material modifications that should be made to the consolidated financial statements referred to above for them to be in conformity with U.S. generally accepted accounting principles.
We have previously audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the consolidated balance sheet of Respironics, Inc. and Subsidiaries as of June 30, 2007, and the related consolidated statements of operations, shareholders equity, and cash flows for the year then ended, not presented herein, and in our report dated August 24, 2007 we expressed an unqualified opinion on those consolidated financial statements and included an explanatory paragraph for the Companys adoption of Statement of Financials Accounting Standards No. 123(R), Share-Based Payment, effective July 1, 2005. In our opinion, the information set forth in the accompanying consolidated balance sheet as of June 30, 2007 is fairly stated, in all material respects, in relation to the consolidated balance sheet from which it has been derived.
| /s/ Ernst & Young LLP |
Pittsburgh, Pennsylvania
February 11, 2008
3
RESPIRONICS, INC. AND SUBSIDIARIES
(Amounts in thousands, except per share data)
See notes to Consolidated Financial Statements.
4
CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
RESPIRONICS, INC. AND SUBSIDIARIES
(Amounts in thousands except per share information)
|
Three months ended
December 31, |
Six months ended
December 31, |
|||||||||||||||
| 2007 | 2006 | 2007 | 2006 | |||||||||||||
|
Net sales |
$ | 343,143 | $ | 288,664 | $ | 654,780 | $ | 555,287 | ||||||||
|
Cost of goods sold |
158,637 | 134,145 | 303,241 | 258,783 | ||||||||||||
| 184,506 | 154,519 | 351,539 | 296,504 | |||||||||||||
|
General and administrative expenses |
47,194 | 38,425 | 94,715 | 73,310 | ||||||||||||
|
Sales, marketing and commission expenses |
67,002 | 54,864 | 130,218 | 112,429 | ||||||||||||
|
Research and development expenses |
18,127 | 15,739 | 36,185 | 30,252 | ||||||||||||
|
In-process research and development expenses |
| | 5,424 | | ||||||||||||
|
Contribution to foundation |
4,000 | | 4,000 | | ||||||||||||
|
Restructuring and acquisition-related expenses |
485 | 1,201 | 1,063 | 2,887 | ||||||||||||
|
Merger expenses |
6,935 | | 6,935 | | ||||||||||||
|
Other income |
(2,047 | ) | (2,855 | ) | (7,271 | ) | (4,840 | ) | ||||||||
| 141,696 | 107,374 | 271,269 | 214,038 | |||||||||||||
|
INCOME BEFORE INCOME TAXES |
42,810 | 47,145 | 80,270 | 82,466 | ||||||||||||
|
Income taxes |
11,958 | 17,546 | 21,949 | 30,798 | ||||||||||||
|
NET INCOME |
$ | 30,852 | $ | 29,599 | $ | 58,321 | $ | 51,668 | ||||||||
|
Basic earnings per share |
$ | 0.42 | $ | 0.41 | $ | 0.79 | $ | 0.71 | ||||||||
|
Weighted average number of basic shares outstanding |
74,036 | 73,024 | 73,950 | 72,930 | ||||||||||||
|
Diluted earnings per share |
$ | 0.41 | $ | 0.40 | $ | 0.78 | $ | 0.70 | ||||||||
|
Weighted average number of diluted shares outstanding |
74,876 | 73,844 | 74,970 | 73,777 | ||||||||||||
See notes to Consolidated Financial Statements.
5
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
RESPIRONICS, INC. AND SUBSIDIARIES
(Amounts in thousands)
| Six months ended December 31, | ||||||||
| 2007 | 2006 | |||||||
|
OPERATING ACTIVITIES |
||||||||
|
Net income |
$ | 58,321 | $ | 51,668 | ||||
|
Adjustments to reconcile net income to net cash provided by operating activities: |
||||||||
|
Depreciation and amortization |
32,900 | 29,496 | ||||||
|
Gain on sale of investment |
| (928 | ) | |||||
|
In-process research and development expenses |
5,424 | | ||||||
|
Stock-based compensation |
7,572 | 6,093 | ||||||
|
Excess tax benefits from share-based payment arrangements |
(4,056 | ) | (2,123 | ) | ||||
|
Provision for bad debts |
695 | 1,264 | ||||||
|
Acquisition earn-out payments, net of provisions |
| (5,365 | ) | |||||
|
Provision (credit) for deferred income taxes |
(1,417 | ) | (2,777 | ) | ||||
|
Changes in operating assets and liabilities: |
||||||||
|
Accounts receivable |
3,834 | (11,036 | ) | |||||
|
Inventories and other current assets |
(13,062 | ) | (19,594 | ) | ||||
|
Accounts payable, accrued expenses, other assets and liabilities |
403 | (5,417 | ) | |||||
|
NET CASH PROVIDED BY OPERATING ACTIVITIES |
90,614 | 41,281 | ||||||
|
INVESTING ACTIVITIES |
||||||||
|
Purchase of property, plant and equipment |
(45,092 | ) | (29,161 | ) | ||||
|
Purchase of short-term investments |
(22,865 | ) | (23,135 | ) | ||||
|
Sales and maturities of short-term investments |
67,439 | 1,200 | ||||||
|
Proceeds from sale of equity investment |
| 928 | ||||||
|
Acquisition of businesses, including additional purchase price payments, intangible assets and other investments, net of cash acquired |
(49,937 | ) | (12,196 | ) | ||||
|
NET CASH USED BY INVESTING ACTIVITIES |
(50,455 | ) | (62,364 | ) | ||||
|
FINANCING ACTIVITIES |
||||||||
|
Proceeds from long-term obligations |
17,013 | 2,681 | ||||||
|
Payment on long-term obligations |
(11,903 | ) | (2,236 | ) | ||||
|
Proceeds from guarantee of third party debt |
| 1,592 | ||||||
|
Issuance of common stock |
12,120 | 6,702 | ||||||
|
Excess tax benefits from share-based payment arrangements |
4,056 | 2,123 | ||||||
|
NET CASH PROVIDED BY FINANCING ACTIVITIES |
21,286 | 10,862 | ||||||
|
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS |
61,445 | (10,221 | ) | |||||
|
Cash and cash equivalents at beginning of period |
231,830 | 259,513 | ||||||
|
CASH AND CASH EQUIVALENTS AT END OF PERIOD |
$ | 293,275 | $ | 249,292 | ||||
See notes to Consolidated Financial Statements
6
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Respironics, Inc. and Subsidiaries
Three and six months ended December 31, 2007
NOTE 1: BASIS OF PRESENTATION
The accompanying unaudited Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation of the financial position of Respironics, Inc. and Subsidiaries (the Company or Respironics) have been included. Operating results for the three months and six months ended December 31, 2007 are not necessarily indicative of the results that may be expected for the year ended June 30, 2008. The amounts and information as of June 30, 2007 set forth in the Consolidated Balance Sheet and notes to the Consolidated Financial Statements that follow were derived from the Companys Annual Report on Form 10-K for the year ended June 30, 2007. For further information, refer to the Consolidated Financial Statements and footnotes thereto included in the Companys Annual Report on Form 10-K for the year ended June 30, 2007.
Within these notes to the financial statements we refer to the three and six months ended December 31, 2007 as the 2007 Quarter and 2007 Period, respectively, and the three and six months ended December 31, 2006 as the 2006 Quarter and 2006 Period, respectively.
On December 20, 2007, the Company entered into a definitive merger agreement pursuant to which Philips Holding USA Inc., a wholly-owned subsidiary of Koninklijke Philips Electronics N.V. (Royal Philips Electronics or Philips), a global leader in healthcare, lighting and consumer lifestyle, agreed to acquire Respironics. According to the terms of the agreement, on January 3, 2008 an indirect, wholly-owned subsidiary of Philips (Moonlight Merger Sub, Inc.) commenced an all-cash tender offer for all of the issued and outstanding shares of Respironics to be followed by a merger in which each remaining un-tendered share of Respironics will be converted into $66 per share. The acquisition will be effected pursuant to a merger agreement and is subject to the terms and conditions of that agreement. Conditions to the completion of the acquisition include the tender of a majority of the outstanding shares of the Company, as well as customary regulatory clearances in the United States and the European Union. United States regulatory approval for the acquisition was received on January 30, 2008, when the Federal Trade Commission granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. Philips has extended the period for the tender offer to February 22, 2008 because not all conditions to the offer had been satisfied or waived by Philips, including the approval by the European Commission. The offer is subject to further extension. Subject to the foregoing conditions, the transaction is expected to close in the Companys third quarter of 2008.
The merger agreement also contains certain termination rights for both Respironics and Philips and further provides that Respironics will be required to pay Philips a termination fee of $175.0 million, plus expenses to a maximum of $10.0 million, if the merger agreement is terminated under certain specified circumstances. In connection with the transaction, Respironics recorded merger expenses, consisting primarily of legal fees, investment banking fees and other related costs of approximately $6.9 million in its Consolidated Statement of Operations for the 2007 Quarter and 2007 Period.
The foregoing description of the merger agreement and the merger does not purport to be complete and is qualified in its entirety by reference to the merger agreement filed as Exhibit 2.1 to our Current Report on Form 8-K dated December 26, 2007, which is incorporated herein by reference.
NOTE 2: SHORT-TERM INVESTMENTS
As of December 31, 2007 and June 30, 2007, the Company invested a portion of its cash into money management funds at high credit quality financial institutions. Short-term investments consist of U.S. Treasury bills, other government securities, commercial paper, and certificates of deposit, with maturities greater than 90 days. These investments are designated as available for sale and are stated at fair value.
NOTE 3: EARNINGS PER SHARE
Earnings per common share is computed in accordance with Financial Accounting Standards Board (FASB) Statement No. 128 Earnings per Share. Presented below is a reconciliation of net income available to common stockholders and the
7
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Respironics, Inc. and Subsidiaries
Three and six months ended December 31, 2007
differences between weighted average common shares outstanding, which are used in computing basic earnings per share, and weighted average common and potential shares outstanding, which are used in computing diluted earnings per share (in thousands except per share information).
|
Three months ended
December 31, |
Six months ended
December 31, |
|||||||||||
| 2007 | 2006 | 2007 | 2006 | |||||||||
|
Numerator: |
||||||||||||
|
Net income |
$ | 30,852 | $ | 29,599 | $ | 58,321 | $ | 51,668 | ||||
|
Denominator: |
||||||||||||
|
Denominator for basic earnings per shareweighted-average shares |
74,036 | 73,024 | 73,950 | 72,930 | ||||||||
|
Effect of dilutive securitiesstock options |
840 | 820 | 1,020 | 847 | ||||||||
|
Denominator for diluted earnings per shareadjusted weighted-average shares |
74,876 | 73,844 | 74,970 | 73,777 | ||||||||
|
Basic Earnings Per Share |
$ | 0.42 | $ | 0.41 | $ | 0.79 | $ | 0.71 | ||||
|
Diluted Earnings Per Share |
$ | 0.41 | $ | 0.40 | $ | 0.78 | $ | 0.70 | ||||
NOTE 4: INVENTORIES
Inventories consisted of the following, net of allowances for obsolete and excess inventories of $25.9 million, and $21.5 million at December 31, 2007 and June 30, 2007, respectively (in thousands):
|
December 31,
2007 |
June 30,
2007 |
|||||
|
Raw materials |
$ | 56,502 | $ | 55,343 | ||
|
Work-in-process |
10,323 | 11,385 | ||||
|
Finished goods |
112,811 | 105,943 | ||||
|
TOTAL |
$ | 179,636 | $ | 172,671 | ||
NOTE 5: DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES
The Companys reporting currency is the U.S. dollar, and a substantial majority of the Companys sales, expenses, and cash flows are transacted in U.S. dollars. The Company also does business in various foreign currencies, primarily the Japanese yen, the euro, and the British pound. The Company also transacts business in the Hong Kong dollar, Canadian dollar, Swiss franc, Australian dollar, Chinese yuan, Swedish krona, Danish krone, Norwegian kroner, Brazilian real, and United Arab Emirates dirham (AED). As part of the Companys risk management strategy, management has put in place a hedging program under which the Company enters into foreign currency option and forward contracts to hedge a portion of cash flows denominated in certain foreign currencies.
The Company enters into foreign currency contracts to reduce the risk that the Companys earnings and cash flows, resulting from certain forecasted and recognized currency transactions, will be affected by changes in foreign currency exchange rates. However, the Company may be impacted by changes in foreign exchange rates related to the portion of the forecasted transactions that are not hedged. The success of the hedging program depends, in part, on forecasts of the Companys transactions in foreign currencies. Hedges are placed for periods consistent with identified exposures, but not longer than the end of the year for which the Company has substantially completed its annual business plan.
During the fourth quarter of 2007, the Company entered into a 14-month Japanese yen-based cross currency interest rate swap, with aggregate notional principal amounts of ¥1.9 billion Japanese Yen (JPY) and $15.8 million that matures on July 31, 2008. This swap effectively hedges a portion of the Companys net investment in its Japanese Fuji subsidiary. During the term of this transaction, the Company will remit to, and receive from, its counterparty interest payments based on
8
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Respironics, Inc. and Subsidiaries
Three and six months ended December 31, 2007
rates that are reset quarterly equal to three-month JPY LIBOR and three-month U.S. LIBOR rates, respectively. The Company has designated this hedging instrument as a hedge of a portion of the net investment in its Japanese Fuji subsidiary, and will use the spot rate method of accounting for changes in the fair value of the hedging instrument attributable to currency rate fluctuations. As such, at December 31, 2007 and June 30, 2007, the fair market value of the hedging instrument attributable to changes in the spot rate of ($1.0) million and $0.4 million, respectively, is recorded as a (debit) credit in other comprehensive income (with a corresponding amount that is classified with prepaid and other current assets in the Consolidated Balance Sheet as of December 31, 2007 and June 30, 2007). The change in fair market value of the cross currency swap offsets the change in a portion of the JPY-denominated net investment in the Companys Japanese Fuji subsidiary. Amounts recorded to foreign currency translation within accumulated other comprehensive income will remain there until the net investment is disposed. The Company recorded $0.2 million and $0.4 million in interest income during the 2007 Quarter and 2007 Period, respectively, in connection with the cross currency interest rate swap.
NOTE 6: COMMITMENTS AND CONTINGENCIES
Invacare Litigation
On March 5, 2004, the Company filed a lawsuit against Invacare Corporation (Invacare) in the United States District Court for the Western District of Pennsylvania alleging that Invacares manufacture, sale and marketing of a new Continuous Positive Airway Pressure (CPAP) device infringes one or more of 11 U.S. patents of the Company. In its complaint, the Company has sought preliminary and permanent injunctive relief, damages and an award of three times actual damages. In its answer to the complaint, Invacare has denied the infringement allegations of the complaint and has asserted that the Companys patents are invalid.
Discovery has concluded, and by Order dated August 30, 2006, the Court decided certain issues regarding the interpretation of patent claims involved in the case. On April 26, 2007, the Court issued a summary judgment decision in which it (1) held the Respironics patent claims asserted to be valid; (2) held that Invacares current CPAP with SoftX product does not infringe three Respironics patents; and (3) held that it could not decide on summary judgment whether a prior version of the Invacare CPAP with SoftX product infringed a fourth Respironics patent. The trial on the infringement claim concerning the prior CPAP with SoftX product began on November 5, 2007 and resulted in a jury verdict in Respironics favor. On January 8, 2008, Respironics filed a Notice of Appeal with the United States Court of Appeals for the Federal Circuit as to the non-infringement aspects of the District Courts prior decisions. On February 4, 2008, Invacare filed a Notice of Cross-Appeal with the United States District Court for the Federal Circuit as to the infringement determination and various other aspects of the case.
On August 6, 2004, Invacare filed a lawsuit against the Company in the United States District Court in the Northern District of Ohio alleging that the Company has engaged in monopolization, restraint of trade and unfair competition in the sale and distribution of sleep apnea products. The lawsuits claims include allegations that the Companys actions and alleged market power have foreclosed competitors from alleged markets and have created markets where there has not been competitive pricing or availability of competitive product offerings. In the lawsuit, Invacare seeks damages in an unspecified amount and to treble such damages pursuant to the antitrust laws, as well as attorneys fees and punitive damages. Invacare also seeks injunctive relief as to certain marketing practices.
By Order dated October 23, 2006, the Court granted partial summary judgment in the Companys favor, dismissing Invacares monopolization, attempted monopolization, price discrimination, and unfair competition claims. The Court also limited future discovery in the case to the two remaining claims, parallel restraint of trade claims under both federal and state law. On October 31, 2006, Invacare filed a motion asking the Court to reconsider portions of its decision granting partial summary judgment. By Order entered on July 19, 2007, the Court denied Invacares motion for reconsideration. The Company continues to vigorously defend itself against these claims.
Shareholder Litigation
On January 8, 2008, a purported class action lawsuit was filed in the Court of Chancery of the State of Delaware against the Company, the members of its Board of Directors, Koninklijke Philips Electronics N.V., Philips Holding USA Inc. and
9
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Respironics, Inc. and Subsidiaries
Three and six months ended December 31, 2007
Moonlight Merger Sub, Inc. (collectively, the defendants). The plaintiff alleges breach of fiduciary duties by the Companys Directors in connection with the merger agreement entered into on December 20, 2007 by Respironics, Philips USA and Moonlight Merger Sub, Inc. and the subsequent tender offer for the Companys shares, commenced on January 3, 2008 by Moonlight Merger Sub, Inc. In the lawsuit, the plaintiff seeks an injunction against the tender offer and the merger agreement as well as unspecified damages, including attorneys fees and costs. On January 10, 2008, the plaintiff filed motions seeking expedited proceedings, including the scheduling of a preliminary injunction hearing before the close of the tender offer and expedited discovery. The defendants opposed the plaintiffs motions. The Vice Chancellor of the Court of Chancery heard arguments on the motions on January 14, 2008, and denied the plaintiffs motions. The Company plans to vigorously defend against any further pursuit of these claims.
Other
The Company is, as a normal part of its business operations, a party to other legal proceedings in addition to those described above and in previous filings of the Company. Legal counsel has been retained for each proceeding, and none of these proceedings is expected to have a material adverse impact on the Companys consolidated results of operations, financial condition or cash flows.
Contingent Obligations Under Recourse Provisions:
In connection with customer leasing programs, the Company uses independent leasing companies for the purpose of providing financing to certain customers for the purchase of the Companys products. In some cases, the Company is contingently liable, in the event of a customer default, to the leasing companies within certain limits for unpaid installment receivables initiated by or transferred to the leasing companies. The transfer of certain of these installment receivables meets the criteria of FASB No. 140 and therefore they are not recorded on the Companys financial statements.
As of December 31, 2007, the total exposure for unpaid installment receivables approximates $10.1 million, compared to $12.2 million as of June 30, 2007. Included in these amounts are unpaid installment receivables totaling $10.1 million and $11.4 million that meet the FASB No. 140 criteria and are not recorded on the Companys consolidated financial statements at December 31, 2007 and June 30, 2007, respectively. The estimated fair value of the Companys contingent recourse guarantee is $3.0 million and $2.2 million as of December 31, 2007 and June 30, 2007, respectively. Approximately 10% and 11% of the Companys net sales were made under these financing arrangements during the 2007 Quarter and 2007 Period, respectively, and 10% and 11% of the Companys net sales were made under these financing arrangements during the 2006 Quarter and 2006 Period, respectively. A portion of these sales was made with recourse. The Company is not dependent on these off-balance sheet arrangements.
Third Party Debt Guarantee
The Company has guaranteed the payment of certain third-party bank debt. The maximum potential amount of future payments that the Company would be required to make, in the event that the third party defaults on its debt obligations, is $7.0 million. The term of the guarantee is five years from its December 2006 inception date. The estimated fair value of the guarantee at December 31, 2007 and June 30, 2007 is $1.5 million; this amount is included in the Consolidated Balance Sheet within other noncurrent liabilities and is being amortized into income over five years. The Company does not believe it is probable that the third party will default on the amount subject to the guarantee.
Product Warranties
Generally, the Companys standard product warranties are for a one- to three-year period (based on the specific product sold and country in which the Company does business) that covers both parts and labor. The Company provides for the estimated cost of product warranties at the time revenue is recognized. The Companys product warranty liability reflects managements best estimate of probable liability under its product warranties. Management estimates the liability based on the Companys stated warranty policies, which project the estimated warranty obligation on a product-by-product basis based on the historical frequency of claims, the cost to replace or repair its products under warranty, and the number of products under warranty based on the warranty terms and historical units shipped. The warranty liability also includes estimated warranty costs that may arise from specific product issues, including product recalls or related field actions. The Company
10
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Respironics, Inc. and Subsidiaries
Three and six months ended December 31, 2007
periodically assesses the adequacy of its recorded warranty liabilities and adjusts the amounts as necessary. The Company also engages in the sale of
extended warranties and long-term service contracts for which revenue is deferred and recognized over the warranty terms, which are generally between two and eight years. Changes in the liability for product warranty and deferred service revenues
Product Warranties
|
Balance as of June 30, 2007 |
$ | 23,954 | ||
|
Warranty accruals during the period |
8,789 | |||
|
Service costs incurred during the period |
(5,132 | ) | ||
|
Balance at December 31, 2007 |
$ | 27,611 | ||
Deferred Service Revenues
|
Balance as of June 30, 2007 |
$ | 9,296 | ||
|
Revenues deferred during the period |
3,648 | |||
|
Obligations transferred with sale of oximetry product line (see Note 10) |
(553 | ) | ||
|
Amounts recorded as revenue during the period |
(2,266 | ) | ||
|
Balance at December 31, 2007 |
$ | 10,125 | ||
The accruals for product warranties and deferred service revenues are classified with accrued expenses and other current liabilities in the Consolidated Balance Sheet.
NOTE 7: FAIR VALUE OF FINANCIAL INSTRUMENTS
The following methods and assumptions were used to estimate the fair value of financial instruments:
Cash and cash equivalents
The carrying amount of cash and cash equivalents, which include investments readily convertible to known amounts of cash with original maturities of 90 days or less, approximate fair value because of the short maturity of those investments.
Short-term investments
Short-term investments are recorded in the Consolidated Balance Sheet at fair value. Fair values are based on quoted market prices, estimates from brokers, and other appropriate valuation techniques. The fair value estimates do not necessarily reflect the values that could be realized in the current market on any one day.
Long-term obligations
The fair values of long-term debt obligations are established from the market values of similar issues. The carrying amounts of the Companys obligations approximate their fair values at December 31, 2007 and June 30, 2007.
Foreign currency exchange derivative contracts
Foreign currency exchange derivative contracts are recorded in the Consolidated Balance Sheet at fair value. As of December 31, 2007 and June 30, 2007, foreign currency contracts with a fair value of ($1.0) million and $0.4 million, respectively, are recorded with prepaid expenses and other current assets.
NOTE 8: STOCK OPTIONS AND PURCHASE PLANS
As of December 31, 2007 the Company maintained two active employee stock option plans: the 2000 Stock Incentive Plan and the 2006 Stock Incentive Plan. The 2007 Employee Stock Purchase Plan was suspended on December 20, 2007, the date of the announced tender offer and merger with Philips discussed in Note 1. These share based compensation plans are described more fully in Note N of the Consolidated Financial Statements included in the Companys June 30, 2007 Annual Report on Form 10-K.
11
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Respironics, Inc. and Subsidiaries
Three and six months ended December 31, 2007
The Company adopted FASB Statement No. 123 (Revised 2004)Share-Based Payment (FASB No. 123(R)) on July 1, 2005 using the modified prospective method. Stock-based compensation expense was $3.9 million ($2.6 million after tax, or $0.03 per share) and $3.1 million ($2.0 million after tax, or $0.03 per share) in the 2007 Quarter and 2006 Quarter, respectively. Stock-based compensation expense was $7.6 million ($5.1 million after tax, or $0.06 per share) and $6.1 million ($4.1 million after tax, or $0.05 per share) in the 2007 Period and 2006 Period, respectively.
Stock based compensation attributable to the stock option and purchase plans were as follows (in thousands):
|
Three months ended
December 31, |
Six months ended
December 31, |
|||||||||||
| 2007 1 | 2006 | 2007 1 | 2006 | |||||||||
|
Stock Option Plans |
$ | 3,614 | $ | 2,914 | $ | 7,046 | $ | 5,713 | ||||
|
Employee Stock Purchase Plan |
289 | 143 | 526 | 380 | ||||||||
|
Total Stock Compensation Expense |
$ | 3,903 | $ | 3,057 | $ | 7,572 | $ | 6,093 | ||||
|
1 |
The Employee Stock Purchase Plan was suspended on December 20, 2007, the date of the announced tender offer and merger with Philips discussed in Note 1. The stock options outstanding under the stock option plans will have a modification of the requisite service period to vest 100% immediately before the merger discussed in Note 1 is completed. |
NOTE 9: COMPREHENSIVE INCOME
The components of comprehensive income are as follows (in thousands):
|
Three months ended
December 31, |
Six months ended
December 31, |
|||||||||||||||
| 2007 | 2006 | 2007 | 2006 | |||||||||||||
|
Net Income |
$ | 30,852 | $ | 29,599 | $ | 58,321 | $ | 51,668 | ||||||||
|
Foreign currency translation gains |
1,446 | 2,849 | 8,183 | 4,021 | ||||||||||||
|
Unrealized gains on derivatives qualifying as hedges |
(388 | ) | | (950 | ) | | ||||||||||
|
Unrealized gain on short-term investments |
3 | (6 | ) | 3 | (2 | ) | ||||||||||
|
Total Comprehensive Income |
$ | 31,913 | $ | 32,422 | $ | 65,557 | $ | 55,687 | ||||||||
NOTE 10: ACQUISITIONS AND DISPOSITIONS
Acquisitions
Mayo On January 2, 2007, the Company acquired the homecare assets of its Australian distributor, Mayo Healthcare Pty Ltd (Mayo). The acquisition provides the Company with a direct presence in the Australian sleep therapy, home noninvasive ventilation and oxygen markets. The purchase price totaled approximately $6.2 million, There are additional accrued payments based on the first year of operation as specified in the stock purchase agreement and there are provisions for additional payments to be made based on operating performance through 2009. The results of operations of the acquired business are included in the Companys Consolidated Statements of Operations beginning on the acquisition date, January 2, 2007. The acquisition did not materially impact the Companys net sales or net income during the 2007 Quarter or 2007 Period.
12
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Respironics, Inc. and Subsidiaries
Three and six months ended December 31, 2007
Emerson On April 3, 2007, the Company acquired the assets of J. H. Emerson Company (Emerson) for a cash purchase price of $23.7 million (including transaction costs). Emerson, located in Cambridge, Massachusetts, is a manufacturer, supplier, and wholesaler of the CoughAssist ® which helps patients to clear broncho-pulmonary secretions to reduce the risk of respiratory complications. Prior to the acquisition, Emerson was the Companys supplier of the CoughAssist ® . The acquisition of the Emerson assets further expands the Companys portfolio of Home Respiratory Care products and enables the Company to better secure the needs of respiratory impaired patients. The results of operations of the Emerson business are included in the Companys Consolidated Statement of Operations beginning on the acquisition date, April 3, 2007. The acquisition did not materially impact the Companys net sales or net income during the 2007 Quarter or 2007 Period.
Apollo On October 2, 2007, the Company acquired 100% of the outstanding shares of Apollo Light Systems, Inc. (Apollo), a privately-held company, located in American Fork, Utah, which manufactures light therapy systems for melatonin suppression and circadian rhythm sleep disorders. The cash purchase price for Apollo was $7.3 million with provisions for additional payments to be made based on its operating performance over the next year. Total potential earn-out payments are less than the base purchase price. The acquisition did not materially impact the Companys net sales or net income during the 2007 Quarter or 2007 Period.
Pro-Tech On December 3, 2007, the Company acquired Pro-Tech Systems (Pro-Tech), a manufacturer of sleep diagnostic accessories for the Companys Alice ® sleep diagnostic products, for $22.9 million. Pro-Tech, located in a suburb of Seattle, Washington, provides the Company with a complementary replaceable sensor business to its capital purchase diagnostic devices. This acquisition did not materially impact the 2007 Quarter or 2007 Period.
Other During the year ended June 30, 2007, the Company acquired the majority of the stock of its distributors in Norway and Denmark, totaling $7.2 million (including transaction costs). These acquisitions did not materially impact the Companys net sales or net income during the 2007 Quarter or 2007 Period.
In addition, in the 2007 Period, the Company invested a total of $12.5 million for a majority equity interest in its distributor in Finland and minority equity interests in two sleep companies. The international distributors results of operations are included in the Companys Consolidated Statements of Operations beginning on the acquisition date. One of the sleep companies developed and markets a stress-reducing product to the retail market. The Company is using the cost method of accounting for this investment since its ownership is less than 20% of the outstanding voting stock of the sleep company and the Company determined that it does not exercise significant influence over the sleep company operations. The other company is a development stage sleep company. The Company is using the equity method of accounting for this investment since its ownership is greater than 20%, but less than 50%, of the outstanding voting stock of the development stage company and the Company determined it does have significant influence over the development stage company operations. The Company recorded $5.4 million of in-process research and development expenses related to this investment in the development stage company; this amount is reflected in the Consolidated Statement of Operations for the 2007 Quarter and the 2007 Period.
Dispositions
On October 8, 2007, the Company sold its Novametrix pulse oximetry business to Dixtal Medical, Inc. after deciding to exit this line of business and refocus on its core technologies. As of June 30, 2007, the Companys assets related to this business, which approximated the sales price, were classified in the Consolidated Balance Sheet as assets held for sale within prepaid expenses and other current assets and other (long-term) assets. During the 2007 Quarter, the Company received proceeds approximately equal to the net book value of the assets disposed. The sale transaction did not have a material impact on the Companys Consolidated Statement of Operations during the 2007 Quarter or 2007 Period.
NOTE 11: INCOME TAXES
In June 2006, the FASB issued FASB Interpretation No. 48, Accounting for Uncertainty in Income Taxesan Interpretation of FASB Statement No. 109 (FIN 48), which became effective for the Company on July 1, 2007. FIN 48 prescribes a comprehensive model for how companies should recognize, measure, present and disclose in their financial statements uncertain tax positions taken or expected to be taken on an income tax return. Under FIN 48, tax positions should initially be recognized in the financial statements when it is more likely than not the position will be sustained upon examination by the
13
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Respironics, Inc. and Subsidiaries
Three and six months ended December 31, 2007
tax authorities. Such tax positions should be initially and subsequently measured as the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate settlement with the tax authority assuming full knowledge of the position and all relevant facts.
The Company adopted the provisions of FIN 48 on July 1, 2007. As a result of the implementation of FIN 48, the Company recognized a net $3.9 million increase in the liability for unrecognized tax benefits which was accounted for as a reduction to the July 1, 2007 balance of retained earnings. After recognition of these items in connection with the implementation of FIN 48, the total liability for unrecognized tax benefits at July 1, 2007 was $20.8 million. Of this total, $16.1 million of net tax benefits would reduce the Companys effective tax rate if the tax benefits were recognized in the financial statements. At December 31, 2007, the Companys total liability for unrecognized net tax benefits was $25.9 million, of which $21.2 million would reduce the effective tax rate.
The Company recognizes interest and penalties accrued related to unrecognized tax benefits in income tax expense. The total amount of accrued interest and penalties included in the FIN 48 liability above as of July 1, 2007 was $3.8 million. The Company recognized $0.4 million of interest and penalties in income tax expense for the 2007 Quarter and $0.8 million for the 2007 Period and at December 31, 2007 the total amount of accrued interest and penalties included in the FIN 48 liability was $4.5 million.
As of December 31, 2007, the Company is not aware of any positions for which it is reasonably possible that the total amounts of unrecognized tax benefits will significantly increase or decrease within the next 12 months.
The tax years 2003-2006 remain open to examination by the major taxing authority jurisdictions to which the Company is subject.
The Companys effective income tax rate was approximately 28% for the 2007 Quarter and 37% for the 2006 Quarter. The lower rate in the current Quarter was related to the establishment of the patient interface manufacturing center of excellence in the Asia Pacific Region. The effective income tax rate for the 2007 and 2006 periods were approximately 27% and 37%, respectively. The lower rate in the 2007 Period was also related to the establishment of the patient interface manufacturing center of excellence in the Asia Pacific Region and other items.
NOTE 12: RECENT ACCOUNTING PRONOUNCEMENTS
In September 2006, the FASB issued Statement No. 157, Fair Value Measurements (FASB No. 157). FASB No. 157 establishes a framework for measuring fair value and expands disclosures about fair value measurements. The changes to current practice resulting from the application of this Statement relate to the definition of fair value, the methods used to measure fair value, and the expanded disclosures about fair value measurements. FASB No. 157 is effective for financial statements issued for fiscal years beginning after November 15, 2007, and interim periods within those fiscal years. However, the FASB, at a board meeting late in 2007, granted a one year deferral of this implementation for nonfinancial assets and liabilities. The Company will be required to adopt the provisions of FASB No. 157 on July 1, 2008, for financial assets and liabilities, and is currently evaluating the impact of such adoption on its Consolidated Financial Statements.
In February 2007, the FASB issued Statement No. 159, The Fair Value Option for Financial Assets and Financial Liabilities (FASB No. 159). This Standard allows companies to elect to follow fair value accounting for certain financial assets and liabilities in an effort to mitigate volatility in earnings without having to apply complex hedge accounting provisions. FASB No. 159 is applicable only to certain financial instruments and is effective for fiscal years beginning after November 15, 2007. The Company may adopt the provisions of FASB No. 159 on July 1, 2008, and is currently evaluating the impact of this optional adoption on its Consolidated Financial Statements.
In December 2007, the FASB issued Statement No. 141 (R), Business Combinations, which requires the acquiring entity in a business combination to recognize all (and only) the assets acquired and liabilities assumed in the transaction; establishes the acquisition-date fair value as the measurement objective for all assets acquired and liabilities assumed; and requires the acquirer to disclose to investors and other users all of the information needed to evaluate and understand the nature and financial effect of the business combination. This is effective for fiscal years beginning after December 15, 2008 with adoption by the Company on July 1, 2009. An evaluation of the impact of this adoption on the Companys Consolidated Financial Statements is being undertaken.
Also in December 2007, the FASB issued Statement No. 160, Non-controlling Interests in Consolidated Financial Statements (FASB No. 160), which is effective for fiscal years beginning after December 15, 2008. This statement requires all entities to report non-controlling (minority) interests in subsidiaries in the same manner as equity in the consolidated
14
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Respironics, Inc. and Subsidiaries
Three and six months ended December 31, 2007
financial statements. This eliminates the diversity that currently exists in accounting for transactions between an entity and non-controlling interests by requiring that they be treated as equity transactions. The Company will be required to adopt the provisions of FASB No. 160 on July 1, 2009 and is currently evaluating the impact of such adoption on its Consolidated Financial Statements.
****************
CAUTIONARY STATEMENT FOR PURPOSES OF THE SAFE HARBOR PROVISIONS OF THE PRIVATE SECURITIES REFORM ACT OF 1995
The statements contained in this Quarterly Report on Form 10-Q, including those contained in Item 2 Managements Discussion and Analysis of Financial Condition and Results of Operations, along with statements in reports filed with the Securities and Exchange Commission (SEC), external documents and oral presentations, which are not historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21B of the Securities and Exchange Act of 1934, as amended. These forward-looking statements represent the Companys present expectations or beliefs concerning future events. The Company cautions that such statements are qualified by important factors that could cause actual results to differ materially from the expected results included in the forward-looking statements. Those factors include, but are not limited to, the following: the impact of the pending merger agreement with Philips, developments in the healthcare industry; the success of the Companys marketing, sales, and promotion programs; future sales, acceptance, and quality of the Companys products and programs; the results of clinical trials; the timing and success of new product introductions; new product development; anticipated cost savings; FDA and other regulatory requirements, enforcement actions, product recalls or related field actions; future results from acquisitions and strategic investments; growth rates in foreign markets; regulations and other factors affecting operations and sales outside the United States; foreign currency fluctuations; the effects of a major natural disaster, cyber-attack or other catastrophic event that results in the destruction or disruption of any critical business or information technology systems; customer consolidation and concentration; increasing price competition and other competitive factors in the manufacture, distribution, and sale of products; interest rate fluctuations; expiration of intellectual property rights; intellectual property and related litigation; other litigation; future levels of earnings and revenues; the number of equity awards granted to employees and changes in the Companys stock price; and third party reimbursement; all of which are subject to change. In addition, completion of the Companys tender offer and merger with Philips is subject to conditions, including satisfaction of a minimum tender condition and the need for regulatory approval, and there can be no assurance those conditions can be satisfied or that the transactions described in Note 1 to this Quarterly Report on Form 10-Q will be completed.
15
Respironics, Inc. and Subsidiaries
Three and six months ended December 31, 2007
| Item 2. | Managements Discussion and Analysis of Financial Condition and Results of Operations |
Within this discussion of financial condition and results of operations we refer to the three and six months ended December 31, 2007 as the 2007 Quarter and 2007 Period, respectively, and the three and six months ended December 31, 2006 as the 2006 Quarter and 2006 Period, respectively.
EXECUTIVE SUMMARY
Net sales for the 2007 Quarter totaled $343.1 million, which represents an increase of 19% over the $288.7 million achieved by the Company in the 2006 Quarter. The Companys recent acquisitions added approximately $8.9 million of revenues during the 2007 Quarter, and favorable changes in foreign currency rates added approximately $3.7 million. Together, acquired revenues and foreign currency rate changes represented 4% of the revenue growth in the 2007 Quarter. Consolidated revenue growth during the 2007 Quarter on an organic, constant-currency basis was 15% compared to the 2006 Quarter. As more fully described below, the Companys revenue growth during the 2007 Quarter was well balanced across key product groups and geographic locations.
Net income for the current quarter was $30.9 million, or $0.41 per diluted share, including $6.9 million of merger expenses on a pre-tax basis (or $0.06 per share after tax) related to the Companys signed merger agreement with Royal Philips Electronics and stock compensation expense totaling $3.9 million on a pre-tax basis (or $0.03 per diluted share after tax). The merger expenses include fees to financial advisory firms that became payable upon execution of the merger agreement on December 20, 2007 and legal fees incurred during the 2007 Quarter. Based on strong operating results during the 2007 Quarter including lower income tax expenses, the Company also contributed $4.0 million to the Respironics Sleep and Respiratory Research Foundation (the Foundation) and incurred $1.4 million of expenses related to additional investments in a development stage sleep company. Additionally, the Company contributed to performance-based employee compensation plans at higher than planned levels based on operating results exceeding plan during the 2007 Quarter.
During the 2007 Quarter the Company made in excess of $35.0 million of strategic investments and acquisition-related payments. In addition, the Company invested $3.0 million during the 2007 Quarter for its new $32 million, 165,000-square-foot manufacturing facility which will be located approximately seven miles from Respironics U.S. headquarters and current manufacturing site in Murrysville, Pennsylvania and will focus on the production of its sleep therapy devices.
RESULTS OF OPERATIONS
(In thousands except percentages and per share data)
|
Three months ended
December 31, |
%
Incr (Decr) |
Six months ended
December 31, |
%
Incr (Decr) |
|||||||||||||||||||
| 2007 | 2006 | 2007 | 2006 | |||||||||||||||||||
|
Net Sales |
$ | 343,143 | $ | 288,664 | 19 | % | $ | 654,780 | $ | 555,287 | 18 | % | ||||||||||
|
Cost of goods sold |
158,637 | 134,145 | 18 | % | 303,241 | 258,783 | 17 | % | ||||||||||||||
| 184,506 | 154,519 | 19 | % | 351,539 | 296,504 | 19 | % | |||||||||||||||
|
General and administrative |
47,194 | 38,425 | 23 | % | 94,715 | 73,310 | 29 | % | ||||||||||||||
|
Sales, marketing and commission |
67,002 | 54,864 | 22 | % | 130,218 | 112,429 | 16 | % | ||||||||||||||
|
Research and development |
18,127 | 15,739 | 15 | % | 36,185 | 30,252 | 20 | % | ||||||||||||||
|
In-process research and development |
| | 5,424 | | ||||||||||||||||||
|
Contribution to foundation |
4,000 | | 4,000 | | ||||||||||||||||||
|
Restructuring and acquisition-related |
485 | 1,201 | 1,063 | 2,887 | ||||||||||||||||||
|
Merger |
6,935 | | 6,935 | | ||||||||||||||||||
|
Total expenses |
143,743 | 110,229 | 278,540 | 218,878 | ||||||||||||||||||
|
Other income |
(2,047 | ) | (2,855 | ) | (7,271 | ) | (4,840 | ) | ||||||||||||||
|
INCOME BEFORE INCOME TAXES |
42,810 | 47,145 | (9 | )% | 80,270 | 82,466 | (3 | )% | ||||||||||||||
|
Income taxes |
11,958 | 17,546 | (32 | )% | 21,949 | 30,798 | (29 | )% | ||||||||||||||
|
NET INCOME |
$ | 30,852 | $ | 29,599 | 4 | % | 58,321 | $ | 51,668 | 13 | % | |||||||||||
|
Diluted earnings per share |
$ | 0.41 | $ | 0.40 | 3 | % | $ | 0.78 | $ | 0.70 | 11 | % | ||||||||||
|
Diluted shares outstanding |
74,876 | 73,844 | 74,970 | 73,777 | ||||||||||||||||||
16
Respironics, Inc. and Subsidiaries
Three and six months ended December 31, 2007
Net Sales Net sales for the 2007 Quarter were $343.1 million representing a 19% increase over the net sales of $288.7 million recorded for the 2006 Quarter, and net sales for the 2007 Period were $654.8 million which was an 18% increase over the net sales of $555.3 million for the 2006 Period. Overall, acquired revenues and the impact of foreign currency exchange rate changes, in the aggregate, had a 4% positive impact on revenues during the 2007 Quarter.
The Companys sales growth occurred across all product groups during the 2007 Quarter and Period and is summarized as follows (in thousands):
|
Three months ended
December 31, |
Increase |
Six months ended
December 31, |
Increase | |||||||||||||||||||||
|
Product Group |
2007 | 2006 | $ | % | 2007 | 2006 | $ | % | ||||||||||||||||
|
Domestic Sleep and Home Respiratory |
$ | 164,049 | $ | 138,553 | $ | 25,496 | 18 | % | $ | 324,811 | $ | 276,810 | $ | 48,001 | 17 | % | ||||||||
|
Domestic Hospital |
58,318 | 54,610 | 3,708 | 7 | % | 106,517 | 97,947 | 8,570 | 9 | % | ||||||||||||||
|
International |
120,776 | 95,501 | 25,275 | 26 | % | 223,452 | 180,530 | 42,922 | 24 | % | ||||||||||||||
|
Total |
$ | 343,143 | $ | 288,664 | $ | 54,479 | 19 | % | $ | 654,780 | $ | 555,287 | $ | 99,493 | 18 | % | ||||||||
The Companys domestic Sleep and Home Respiratory revenue gains during the 2007 Quarter were led by increases of $18.4 million (16%) in sleep therapy product revenues over the 2006 Quarter. The Companys growth in OSA was driven by the ongoing success of the M Series platform of sleep therapy devices including proprietary breathing modalities like A-Flex, and a broad range of patient interface products including OptiLife and the Companys ComfortGel mask. Further, Home Respiratory Care products contributed to the Companys growth in the 2007 Quarter, as the recently introduced EverFlo Stationary Oxygen Concentrator and EverGo Portable Oxygen Concentrator continued to gain market acceptance. Those same drivers resulted in overall revenue increases in Sleep and Home Respiratory revenue for the 2007 Period of $48.0 million or 17%.
Sales of domestic Hospital products in the 2007 Quarter increased by $3.7 million (7%) as compared to the 2006 Quarter. The Company received positive contributions from sales of domestic Respiratory Drug Delivery products (consisting of general-purpose asthma and nebulizer products as well as advanced respiratory drug delivery systems) and Childrens Medical Ventures products (consisting of infant monitors, bilirubin devices, and developmental care products) during the 2007 Quarter. These gains were partially offset by domestic Critical Care products (consisting of ventilation therapy and cardio-respiratory monitoring products) performance. The Companys domestic Hospital products revenues increased by $8.6 million in the 2007 Period, a 9% increase over the 2006 Period.
The growth in International revenue during the 2007 Quarter included increased sales of both Sleep and Home Respiratory and Hospital products. The most significant increase was driven by sleep therapy, which increased by $9.6 million (22%) during the 2007 Quarter. The Company also experienced substantial growth in sales of Home Respiratory Care products during the 2007 Quarter. Additionally, International Hospital product sales increased by $6.8 million (24%) for the 2007 Quarter, driven by strong performances across all major Hospital product categories. The Companys international revenue growth occurred across key markets, especially Europe, the Far East / Asia Pacific and the International Americas. International revenue grew by $42.9 million (24%) during the 2007 Period driven by both Sleep and Home Respiratory as well as Hospital sales.
17
Respironics, Inc. and Subsidiaries
Three and six months ended December 31, 2007
The Companys sales for each of the product groups, as a percentage of total sales, were as follows:
Gross Profit The Companys gross profit was 54% of net sales for the 2007 Quarter and Period, and 54% and 53% for the 2006 Quarter and Period, respectively. Gross margin as a percent of sales was comparable year-over-year. Factors that influence the Companys gross profit include sales mix (between product groups as well as geographies), manufacturing throughput, raw material prices, and direct and indirect manufacturing costs including freight expenses.
General and Administrative Expenses General and administrative expenses were $47.2 million (14% of net sales) for the 2007 Quarter, compared to $38.4 million (13% of net sales) for the 2006 Quarter and $94.7 million (14% of net sales) for the 2007 Period, compared to $73.3 million (13% of net sales) for the 2006 Period. The increase for both the Quarter and the Period was due primarily to contributions to the Companys employee incentive compensation plans, consistent with the Companys financial performance achieved during the Quarter and Period and other expenses incurred consistent with the Companys growth, including salaries, warranty and acquired company expenses.
Sales, Marketing and Commission Expenses Sales, marketing and commission expenses were $67.0 million (20% of net sales) for the 2007 Quarter, compared to $54.9 million (19% of net sales) for the 2006 Quarter and $130.2 million (20% of net sales) for the 2007 Period, compared to $112.4 million (20% of net sales) for the 2006 Period. The increase was driven by the Companys continued investments in sales and marketing programs, especially the launch of new products, and sales force, meeting and trade show expenses that occurred during the Quarter and Period, as well as acquired company expenses. In addition, the Companys sales, marketing and commissions expenses increased during the 2007 Quarter and Period as a result of changes in foreign currency exchange rates.
Research and Development Expenses Research and development expenses were $18.1 million (5% of net sales) for the 2007 Quarter, compared to $15.7 million (5% of net sales) for the 2006 Quarter and $36.2 million (6% of net sales) for the 2007 Period, compared to $30.3 million (5% of net sales) for the 2006 Period. The increase for the Quarter and Period was due to the Companys continuing commitment to research and development in its core markets and product groups, including several new patient interface products in development for use in sleep therapy and hospital ventilation, as well as on-going work on new sleep therapy and ventilation device platforms and breathing algorithms. The Company also continues to make investments in opportunities outside of its core product and market groups.
In-process Research and Development Expenses During the 2007 Period, the Company recognized $5.4 million of in-process research and development expenses related to an equity investment in a development stage sleep company.
Contribution to the Foundation During the 2007 Quarter the Company made a contribution of $4.0 million to the Respironics Sleep and Respiratory Research Foundation. This was the only contribution made during the 2007 Period and no contributions were made to the Foundation during the 2006 Quarter and Period. The Foundation was formed for scientific, educational, and charitable purposes and is used to promote awareness of, and research into, the medical consequences of sleep and respiratory problems.
Restructuring and Acquisition-Related Expenses The Company incurred restructuring and acquisition-related expenses of $0.5 million and $1.1 million for the 2007 Quarter and 2007 Period, respectively, primarily related to the integration of acquired companies and other costs. During the 2006 Quarter and Period the Company incurred restructuring and acquisition-related expenses of $1.2 million and $2.9 million, respectively, related primarily to the integration of acquired companies, restructuring of operations at certain facilities and other costs.
Merger Expenses The Company incurred investment banking fees, legal fees and other costs related to the merger transaction discussed in Note 1 to the Consolidated Financial Statements. These totaled approximately $6.9 million for the 2007 Quarter and Period.
18
Respironics, Inc. and Subsidiaries
Three and six months ended December 31, 2007
Other Income Other income was $2.0 million for the 2007 Quarter and $7.3 million for the 2007 Period, compared to $2.9 million for the 2006 Quarter and $4.8 million for the 2006 Period. Other income in all quarters and periods presented includes net interest income and net realized and unrealized foreign currency exchange gains (losses). Other income in the 2007 Quarter and 2007 Period includes a gain of approximately $1.0 million and $3.9 million, respectively, resulting from the strengthening of certain foreign currency exchange rates against the U.S. dollar.
Income Taxes The Companys effective income tax rate was approximately 28% for the 2007 Quarter and 37% for the 2006 Quarter. The lower rate in the current Quarter was related to the establishment of the patient interface manufacturing center of excellence in the Asia Pacific Region. The effective income tax rate for the 2007 and 2006 Periods was approximately 27% and 37%, respectively. The lower rate in the 2007 Period was also related to the establishment of the patient interface manufacturing center of excellence in the Asia Pacific Region and other items.
Net Income As a result of the factors described above, the Companys net income was $30.9 million (9% of net sales) or $0.41 per diluted share for the 2007 Quarter, compared to net income of $29.6 million (10% of net sales) or $0.40 per diluted share for the 2006 Quarter.
Net income was $58.3 million (9% of net sales) or $0.78 per diluted share for
FINANCIAL CONDITION, LIQUIDITY AND CAPITAL RESOURCES
Cash Flows
| (in thousands) | 2007 | 2006 |
Increases in
Cash |
||||||||
|
Net cash provided by operating activities |
$ | 90,614 | $ | 41,281 | $ | 49,333 | |||||
|
Net cash used in investing activities |
$ | (50,455 | ) | $ | (62,364 | ) | $ | 11,909 | |||
|
Net cash provided by financing activities |
$ | 21,286 | $ | 10,862 | $ | 10,424 | |||||
The increase in cash provided by operating activities of $49.3 million was due to higher net income before the impact of depreciation, amortization, and stock-based compensation expenses. During the 2007 Period, accounts receivable decreased by $3.8 million compared to an increase of $11.0 million in the comparable period last year; the Companys days sales outstanding were 58 days at December 31, 2007 compared to 62 days at December 31, 2006. Investment in inventories and other current assets was $13.1 million for the 2007 Period compared to $19.6 million for the 2006 Period. This $6.5 million reduction compared to the 2006 Period was primarily due to the Companys efforts to decrease inventory levels. The Company decreased accounts payable, other assets and liabilities by $0.4 million in the 2007 Period compared to an increase of $5.4 million during the 2006 Period.
During the 2007 Period the Company used $22.9 million of cash to purchase short-term investments, and it received $67.4 million of proceeds from the sales and maturities of short-term investments. During the 2006 Period, the Company used $23.1 million of cash to purchase short-term investments and received $1.2 million of proceeds from the sales and maturities of short-term investments. During the 2007 and 2006 Periods, respectively, the Company paid $49.9 million and $12.2 million (net of cash acquired) to acquire businesses, intangible assets, and other investments, including additional purchase price payments for previously acquired businesses. These acquisition-related payments are more fully described in Note 10 to the Consolidated Financial Statements. Additionally, cash used by investing activities included capital expenditures of $45.1 million and $29.2 million during the 2007 and 2006 Periods, respectively. These capital expenditures included the purchase of leasehold improvements, production equipment, computer hardware and software, telecommunications and office equipment, and the production of equipment leased to customers. The Company continues to invest in several growth supporting initiatives, including various facility expansions, a new manufacturing facility being built near the Murrysville, Pennsylvania headquarters, and production equipment for new products. Funds utilized for investing activities in the 2007 Period were provided by the proceeds from the sale and maturity of short-term investments and positive cash flows from operating activities.
19
Respironics, Inc. and Subsidiaries
Three and six months ended December 31, 2007
Cash provided by financing activities in the 2007 Period consists of $12.1 million of proceeds from the issuance of common stock under the Companys stock option plans and $17.0 million of proceeds from short-term borrowings and equipment financing at the Companys Fuji subsidiary. These proceeds were partially offset by payments on these equipment financing arrangements and other long-term borrowings of $11.9 million. Cash provided by financing activities also includes $4.1 million of excess tax benefits from share-based payment arrangements. Net cash provided by financing activities during the 2006 Period consists of $6.7 million of proceeds from the issuance of common stock under the Companys stock option plans and $2.7 million of proceeds from short-term borrowings and equipment financing at the Companys Fuji subsidiary. These proceeds were partially offset by payments on theses equipment financing arrangements and other long-term borrowings of $2.2 million. Cash provided by financing activities during the 2006 Period also includes $2.1 million of excess tax benefits from share-based payment arrangements and $1.6 million of proceeds from the guarantee of third party debt.
The Company had working capital of $564.3 million at December 31, 2007 and $537.1 million at June 30, 2007.
The Company believes that its sources of funding, which consist of projected positive cash flow from operating activities, the availability of additional funds under its revolving credit facility (totaling approximately $148.4 million at December 31, 2007), and its accumulated cash, cash equivalents, and short-term investments, will be sufficient to meet its current and presently anticipated short-term and long-term needs for operating activities and typical investing activities, and financing activities.
The Company will, however, have substantial cash requirements for additional merger transaction-related expenses and stock option buy-outs immediately prior to the closing of the transaction. It may be necessary to borrow amounts in excess of the current revolver capacity from Philips or other sources to meet these obligations or Philips could pay certain of these obligations directly.
CONTRACTUAL OBLIGATIONS AND OFF-BALANCE SHEET ARRANGEMENTS
The Company has contractual financial obligations and commercial financial commitments consisting primarily of long-term debt, capital lease obligations, and non-cancelable operating leases. The Companys contractual obligations and commercial commitments are described in Item 7. Managements Discussion and Analysis Contractual Obligations and Commitments in its Annual Report on Form 10-K filed with the Securities and Exchange Commission for the year ended June 30, 2007. The composition and nature of these obligations and commitments have not changed materially since June 30, 2007. See Note 6 to the Consolidated Financial Statements for additional information about certain obligations and commitments.
On August 19, 2002 and as subsequently amended, the Company entered into a revolving credit agreement with a group of banks under which a total of $150.0 million is available through August 31, 2009. The revolving credit agreement is unsecured and contains certain financial covenants with which the Company must comply. The Company is currently in compliance with these covenants. The interest rate on the revolving credit facility is based on a spread over the London Interbank Offered Rate (LIBOR). As of December 31, 2007, no borrowings are outstanding under the revolving credit agreement.
CRITICAL ACCOUNTING POLICIES
The Companys Consolidated Financial Statements are prepared in accordance with U.S. generally accepted accounting principles, which require the Company to make estimates and assumptions that may affect the reported financial condition and results of operations should actual results differ. The Company bases its estimates and assumptions on the best available information and believes them to be reasonable under the circumstances. There has been no change in the Companys critical accounting policies as disclosed in the Companys Annual Report on Form 10-K for the year ended June 30, 2007, except as discussed below.
Income taxes
In June 2006, the FASB issued FASB Interpretation No. 48, Accounting for Uncertainty in Income Taxesan Interpretation of FASB Statement No. 109 (FIN 48), which became effective for the Company on July 1, 2007. FIN 48 prescribes a comprehensive model for how companies should recognize, measure, present and disclose in their financial statements uncertain tax positions taken or expected to be taken on an income tax return. Under FIN 48, tax positions should initially be recognized in the financial statements when it is more likely than not the position will be sustained upon examination by the tax authorities. Such tax positions should be initially and subsequently measured as the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate settlement with the tax authority assuming full knowledge of the position and all relevant facts.
20
Respironics, Inc. and Subsidiaries
Three and six months ended December 31, 2007
The Company adopted the provisions of FIN 48 on July 1, 2007. As a result of the implementation of FIN 48, the Company recognized a net $3.9 million increase in the liability for unrecognized tax benefits which was accounted for as a reduction to the July 1, 2007 balance of retained earnings. After recognition of these items in connection with the implementation of FIN 48, the total liability for unrecognized tax benefits at July 1, 2007 was $20.8 million. Of this total, $16.1 million of net tax benefits would reduce the Companys effective tax rate if the tax benefits were recognized in the financial statements. At December 31, 2007, the Companys total liability for unrecognized net tax benefits is $25.9 million, of which $21.2 million would reduce the effective tax rate.
The Company recognizes interest and penalties accrued related to unrecognized tax benefits in income tax expense. The total amount of accrued interest and penalties included in the FIN 48 liability above as of July 1, 2007 was $3.8 million. The Company recognized $0.4 million of interest and penalties in income tax expense for the 2007 Quarter and $0.8 million for the 2007 Period and at December 31, 2007 the total amount of accrued interest and penalties included in the FIN 48 liability is $4.5 million.
As of December 31, 2007, the Company is not aware of any positions for which it is reasonably possible that the total amounts of unrecognized tax benefits will significantly increase or decrease within the next 12 months.
The tax years 2003-2006 remain open to examination by the major taxing authority jurisdictions to which the Company is subject.
| Item 3. | Quantitative and Qualitative Disclosures about Market Risk |
Interest Rates Interest rates have not had a significant effect on the Companys business during the periods discussed. All of the Companys long-term obligations are subject to fixed interest rates, and the Company has no interest rate hedging agreements.
Foreign Exchange Rates The Company is exposed to market risk from changes in foreign exchange rates. The Companys functional currency is the U.S. dollar and a substantial majority of the Companys sales, expenses and cash flows are transacted in U.S. dollars. The Company also conducts business in various foreign currencies, primarily the Japanese yen, the euro, and the British pound. Additionally the Company transacts business in the Hong Kong dollar, the Canadian dollar, the Swiss franc, Australian dollar, the Chinese yuan, Swedish krona, Danish krone, Norwegian kroner, Brazilian real, and United Arab Emirates dirham (AED). As part of the Companys risk management strategy, the Company put in place a hedging program under which the Company enters into foreign currency option and forward contracts to hedge a portion of cash flows denominated in certain foreign currencies. These contracts are entered into to reduce the risk that the Companys earnings and cash flows, resulting from certain forecasted and recognized currency transactions, will be affected by changes in foreign currency exchange rates. See Note 5 to the Consolidated Financial Statements for additional information about the Companys foreign currency hedging activities.
Sales denominated in currencies other than the U. S. dollar were $139.0 million (21% of consolidated sales) for the 2007 Period and $100.4 million (18% of consolidated sales) for the 2006 Period. An adverse change of 10% in exchange rates would have resulted in a decrease in sales of $12.6 million for the 2007 Period. Net foreign currency gains (losses) included in the determination of the Companys net income were approximately $1.0 million and ($0.1) million for the 2007 Quarter and 2006 Quarter, respectively, and $3.9 million and ($0.2) million for the 2007 Period and 2006 Period, respectively.
Inflation Inflation has not had a significant effect on the Companys business during the periods discussed.
| Item 4. | Controls and Procedures |
The Chief Executive Officer and the Chief Financial Officer of the Company (its principal executive officer and principal financial officer, respectively) have concluded, based on their evaluation as of the end of the period covered by this quarterly report, that the Companys disclosure controls and procedures are effective to ensure that information required to be disclosed by the Company in the reports filed or submitted by it under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the SECs rules and forms, and include controls and procedures designed to ensure that information required to be disclosed by the Company in such reports is accumulated and communicated to the Companys management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.
21
Respironics, Inc. and Subsidiaries
Three and six months ended December 31, 2007
There has been no change in the Companys internal control over financial reporting during the 2007 Quarter and 2007 Period that has materially affected, or is reasonably likely to materially affect, the Companys internal control over financial reporting.
| Item 1: | Legal Proceedings. |
Invacare Litigation
On March 5, 2004, the Company filed a lawsuit against Invacare Corporation (Invacare) in the United States District Court for the Western District of Pennsylvania alleging that Invacares manufacture, sale and marketing of a new Continuous Positive Airway Pressure (CPAP) device infringes one or more of 11 U.S. patents of the Company. In its complaint, the Company has sought preliminary and permanent injunctive relief, damages and an award of three times actual damages. In its answer to the complaint, Invacare has denied the infringement allegations of the complaint and has asserted that the Companys patents are invalid.
Discovery has concluded, and by Order dated August 30, 2006, the Court decided certain issues regarding the interpretation of patent claims involved in the case. On April 26, 2007, the Court issued a summary judgment decision in which it (1) held the Respironics patent claims asserted to be valid; (2) held that Invacares current CPAP with SoftX product does not infringe three Respironics patents; and (3) held that it could not decide on summary judgment whether a prior version of the Invacare CPAP with SoftX product infringed a fourth Respironics patent. The trial on the infringement claim concerning the prior CPAP with SoftX product began on November 5, 2007 and resulted in a jury verdict in Respironics favor. On January 8, 2008, Respironics filed a Notice of appeal with the United States Court of appeals for the Federal Circuit as to the non-infringement aspects of the District Courts prior decisions. On February 4, 2008, Invacare filed a Notice of Cross-Appeal with the United States District Court for the Federal Circuit as to the infringement determination and various other aspects of the case.
On August 6, 2004, Invacare filed a lawsuit against the Company in the United States District Court in the Northern District of Ohio alleging that the Company has engaged in monopolization, restraint of trade and unfair competition in the sale and distribution of sleep apnea products. The lawsuits claims include allegations that the Companys actions and alleged market power have foreclosed competitors from alleged markets and have created markets where there has not been competitive pricing or availability of competitive product offerings. In the lawsuit, Invacare seeks damages in an unspecified amount and to treble such damages pursuant to the antitrust laws, as well as attorneys fees and punitive damages. Invacare also seeks injunctive relief as to certain marketing practices.
By Order dated October 23, 2006, the Court granted partial summary judgment in the Companys favor, dismissing Invacares monopolization, attempted monopolization, price discrimination, and unfair competition claims. The Court also limited future discovery in the case to the two remaining claims, parallel restraint of trade claims under both federal and state law. On October 31, 2006, Invacare filed a motion asking the Court to reconsider portions of its decision granting partial summary judgment. By Order entered on July 19, 2007, the Court denied Invacares motion for reconsideration. The Company continues to vigorously defend itself against these claims.
Shareholder Litigation
On January 8, 2008, a purported class action lawsuit was filed in the Court of Chancery of the State of Delaware against the Company, the members of its Board of Directors, Koninklijke Philips Electronics N.V., Philips Holding USA Inc. and Moonlight Merger Sub, Inc. (collectively, the defendants). The plaintiff alleges breach of fiduciary duties by the Companys Directors in connection with the merger agreement entered into on December 20, 2007 by Respironics, Philips USA and Moonlight Merger Sub and the subsequent tender offer for the Companys shares, commenced on January 3, 2008 by Moonlight Merger Sub. In the lawsuit, the plaintiff seeks an injunction against the tender offer and the merger agreement as well as unspecified damages, including attorneys fees and costs. On January 10, 2008, the plaintiff filed motions seeking expedited proceedings, including the scheduling of a preliminary injunction hearing before the close of the tender offer and expedited discovery. The defendants opposed the plaintiffs motions. The Vice Chancellor of the Court of Chancery heard arguments on the plaintiffs motions on January 14, 2008, and denied the motions. The Company plans to vigorously defend against any further pursuit of these claims.
22
Respironics, Inc. and Subsidiaries
Three and six months ended December 31, 2007
Other
The Company is, as a normal part of its business operations, a party to other legal proceedings in addition to those described above and in previous filings of the Company. Legal counsel has been retained for each proceeding, and none of these proceedings is expected to have a material adverse impact on the Companys results of operations, financial condition or cash flows.
| Item 1A: | Risk Factors. |
In the event the Companys proposed merger with Philips is not consummated, its business, results of operations and market price of its common stock could be materially and adversely affected.
The Company entered into a merger agreement with Philips on December 20, 2007, pursuant to which Philips has agreed to acquire Respironics. The announcement and pending completion of the terms of the merger agreement and merger could have an adverse effect on the Companys business generally, its customer relationships and operating results, and its ability to retain employees, including key employees.
In addition, in the event that the conditions to the completion of the merger are not satisfied, including the receipt of regulatory approvals, or an event, change, or other circumstance occurs that could give rise to the termination of the merger agreement, the merger may not be completed.
The Company has already incurred substantial costs in connection with the proposed merger, including legal fees, financial advisory fees and other related costs, and it anticipates incurring additional costs prior to the closing of the merger. If the merger is not completed due to certain circumstances specified in the merger agreement, the Company also may be required to pay Philips a termination fee of $175.0 million, plus expenses, up to a maximum of $10.0 million. Further, if the merger is not completed, the Company may experience negative reactions from the financial markets and its customers, suppliers and employees. Each of the factors described above could materially and adversely affect the Companys business, results of operations and the market price and trading volume of its common stock. In particular, if the merger is not completed for any reason, the market price of the Companys common stock will likely decline, to the extent that the current market price reflects the market assumption that the merger will be completed or the markets perceptions as to the reasons why the merger was not completed.
Restrictions on the conduct of the Companys business prior to the completion of the pending merger with Philips may negatively impact its results of operations and its competitive position.
The Company is subject to certain restrictions under the merger agreement on the conduct of its business prior to the completion of the merger, including not exceeding a certain amount in capital expenditures, not making acquisitions other than those contemplated by the merger agreement or subsequently consented to, not entering into contracts exceeding a certain amount and other matters. These restrictions may prevent the Company from pursuing attractive business opportunities that may arise prior to the completion of the merger with Philips that could be favorable to its operations and its shareholders. As a result, if the proposed merger is not completed, the Companys results of operations and competitive position may be adversely affected.
Other than the two risk factors described above, there were no material changes in the Companys risk factors from the risks disclosed in the Companys Annual Report on Form 10-K for the year ended June 30, 2007.
| Item 2: | Unregistered Sales of Equity Securities and Use of Proceeds. |
None
| Item 3: | Defaults Upon Senior Securities. |
None
23
Respironics, Inc. and Subsidiaries
Three and six months ended December 31, 2007
| Item 4: | Submission of Matters to a Vote of Security Holders. |
At the Respironics, Inc. Annual Meeting of Shareholders on November 13, 2007, the following members were elected to the Board of Directors for a period of three years:
Dr. Cotter, Ms. Littell, Mr. McGinnis and Mr. Reynolds were elected as Directors. Directors whose term of office continued after the meeting were Mr. J. Terry Dewberry, Mr. Donald H. Jones, Mr. Joseph C. Lawyer, Mr. James W. Liken, Ms. Mylle H. Mangum, Mr. Sean C. McDonald, Mr. John L. Miclot, and Mr. John C. Miles II.
Additionally, at the meeting, there was a vote on the following proposal which was approved:
| Item 5: | Other Information. |
None
| Item 6: | Exhibits. |
| Exhibit 15 | Acknowledgement of Ernst & Young LLP. | |
| Exhibit 10.60 | Employment agreement with Gerald E. McGinnis, dated November 13, 2007 | |
| Exhibit 10.61 | Employment agreement with Craig B. Reynolds, dated November 13, 2007 | |
| Exhibit 10.62 | Letter Agreement between Craig B. Reynolds and the Company, dated as of December 20, 2007, filed as Exhibit (e)(3) to the Schedule 14D-9, filed by Respironics, Inc. on January 3, 2008 | |
| Exhibit 10.63 | Letter Agreement between Geoffrey C. Waters and the Company, dated as of December 20, 2007, filed as Exhibit (e)(4) to the Schedule 14D-9, filed by Respironics, Inc. on January 3, 2008 | |
| Exhibit 10.64 | Letter Agreement between Derek Smith and the Company, dated as of December 20, 2007, filed as Exhibit (e)(5) to the Schedule 14D-9, filed by Respironics, Inc. on January 3, 2008 | |
| Exhibit 10.65 | Letter Agreement between Donald J. Spence and the Company, dated as of December 20, 2007, filed as Exhibit (e)(6) to the Schedule 14D-9, filed by Respironics, Inc. on January 3, 2008 | |
| Exhibit 10.66 | Letter Agreement between John L. Miclot and the Company, dated as of December 20, 2007, filed as Exhibit (e)(7) to the Schedule 14D-9, filed by Respironics, Inc. on January 3, 2008 | |
| Exhibit 31.1 | Section 302 Certification of John L. Miclot, President and Chief Executive Officer. | |
| Exhibit 31.2 | Section 302 Certification of Daniel J. Bevevino, Vice President and Chief Financial Officer. | |
| Exhibit 32 | Section 906 Certifications of John L. Miclot, President and Chief Executive Officer and Daniel J. Bevevino, Vice President and Chief Financial Officer. | |
24
Respironics, Inc. and Subsidiaries
Three and six months ended December 31, 2007
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| RESPIRONICS, INC. | ||
| Date: February 11, 2008 |
/ S / D ANIEL J. B EVEVINO |
|
| Daniel J. Bevevino | ||
|
Vice President, and Chief Financial and Principal Accounting Officer |
||
|
Signing on behalf of the registrant and as Chief Financial and Principal Accounting Officer |
||
25
Exhibit 15
Respironics, Inc. and Subsidiaries
Three and six months ended December 31, 2007
Acknowledgement of Independent Registered Public Accounting Firm
Board of Directors
Respironics, Inc. and Subsidiaries
We are aware of the incorporation by reference of our report dated February 11, 2008, with respect to the unaudited Consolidated Interim Financial Statements of Respironics, Inc. and Subsidiaries that are included in its Quarterly Report on Form 10-Q for the three-month and six-month periods ended December 31, 2007 in the following Registration Statements:
| |
Post Effective Amendment No. 1 on Form S-8 to Form S-4 No. 333-43703 pertaining to the Healthdyne Technologies, Inc. 1996 Stock Option Plan, Healthdyne Technologies, Inc. Stock Option Plan, Healthdyne Technologies, Inc. Nonemployee Director Stock Option Plan, and Healthdyne Technologies, Inc. Stock Option Plan II; |
| |
Form S-8 No. 333-16721 pertaining to the Respironics, Inc. Retirement Savings Plan; |
| |
Form S-8 No. 33-89308 and Form S-8 No. 333-74510 pertaining to the 1992 Stock Incentive Plan; |
| |
Form S-8 No. 33-44716 and Form S-8 No. 333-74504 pertaining to the 1991 Nonemployee Directors Stock Option Plan; |
| |
Form S-8 No. 33-36459 pertaining to the Amended and Restated Incentive Stock Option Plan of Respironics, Inc. and Gerald E. McGinnis and the Consulting Agreement dated July 1, 1988 between Respironics, Inc. and Mark H. Sanders, M.D.; |
| |
Form S-8 No. 333-87335 pertaining to the Respironics, Inc. 1997 Non-Employee Directors Fee Plan; |
| |
Form S-8 No. 333-56812 and Form S-8 No. 333-110649 pertaining to the Respironics, Inc. 2000 Stock Incentive Plan; |
| |
Form S-8 No. 333-74506 pertaining to the Respironics, Inc. 2002 Employee Stock Purchase Plan; |
| |
Post Effective Amendment No. 1 on Form S-8 to Form S-4 No. 333-77048 pertaining to the Novametrix Medical Systems Inc. 1990 Stock Option Plan, Novametrix Medical Systems Inc. 1994 Stock Option Plan, Novametrix Medical Systems Inc. 1997 Long-Term Incentive Plan, Novametrix Medical Systems Inc. 1999 Incentive Plan, Novametrix Medical Systems Inc. 2000 Long-Term Incentive Plan, and Novametrix Medical Systems Inc. President & COO Stock Options; |
| |
Form S-8 No. 333-129737 pertaining to the Respironics, Inc. 2006 Stock Incentive Plan; |
| |
Form S-8 No. 333-129738 pertaining to the Respironics, Inc. 2005 Supplemental Executive Retirement Plan and the 2005 Non-Employee Director Deferred Compensation Plan; and |
| |
Form S-8 No. 333-138718 pertaining to the Respironics, Inc. 2007 Employee Stock Purchase Plan. |
| /s/ Ernst & Young LLP |
Pittsburgh, Pennsylvania
February 11, 2008
26
Exhibit 10.60
AMENDED AND RESTATED
EMPLOYMENT AGREEMENT
THIS AGREEMENT, made as of November 13, 2007, by and between RESPIRONICS, INC., a Delaware corporation (the Company ), and GERALD E. McGINNIS, of Export, PA ( Executive ).
W I T N E S S E T H :
WHEREAS, the Company and Executive are currently parties to an Amended and Restated Employment Agreement (as amended and restated from time to time prior to the date of this Agreement, the Original Agreement );
WHEREAS, the Company and Executive wish to amend and restate the Original Agreement as hereinafter provided (such amended and restated Employment Agreement being hereinafter called the Employment Agreement ).
NOW, THEREFORE, intending to be legally bound, the Company agrees to employ Executive, and Executive hereby agrees to be employed by the Company, upon the following terms and conditions:
ARTICLE I
EMPLOYMENT
1.01. Office . Executive is hereby employed as Executive Chairman of the Board of Directors of the Company and in such other executive and managerial capacities as the Board of Directors of the Company may from time to time determine and in such capacity or capacities shall use his best energies or abilities in the performance of his duties hereunder and as prescribed in the By-Laws of the Company. Executive shall not be required to devote more than approximately two-thirds of his working time to the performance of his duties hereunder.
In addition to his duties of presiding at all meetings of shareholders and directors of the Company, Executive shall take a senior leadership role with respect to community relations, employee retention and business development. In furtherance of the foregoing, Executive shall: (a) take all steps which he feels are reasonably required in order to insure that the policies and directions of the Board are being carried out by the Companys management and to assist management in its efforts to do so, (b) together with the Companys President, fulfill the Companys civic and charitable responsibilities along lines from time to time approved by the Board, including making public appearances on behalf of the Company, (c) provide guidance and direction in the acquisition of new products and businesses, (d) provide guidance and direction with respect to Company employees and (e) advise senior management on other significant issues affecting the Company. Executive shall also perform such other duties and responsibilities as the Board of Directors may reasonably require. Executives duties as Executive Chairman of the Board of Directors shall be subject only to the direction and control of the Board of Directors.
1.02. Term . Subject to the terms and provisions of Article II hereof, Executive shall be employed by the Company for a period of three (3) years (the Term ), commencing on the date of this Agreement. Subject to the terms and provisions of Article II hereof, the Term shall automatically be extended for additional three (3) year periods
unless, not less than ninety (90) days prior to the expiration of the first year of the then-current Term, either Executive or the Company shall advise the other that the Term will not be further extended. Term shall also include any extension or renewals of the original Term.
1.03. Base Salary . During the Term, compensation shall be paid to Executive by the Company at the rate of $350,000 per annum (the Base Salary ), payable biweekly. The Base Salary to be paid to Executive may be adjusted upward or downward (but not below the Base Salary) by the Board of Directors of the Company at any time (but not less frequently than annually) based upon Executives contribution to the success of the Company and on such other factors as the Board of Directors of the Company shall deem appropriate.
1.04. Executive Benefits . At all times during the Term, Executive shall have the right to participate in and receive benefits under and in accordance with the then-current provisions of all life, health and accident insurance, hospitalization and other incentive and benefit plans or programs (except for any such plan in which Executive may not participate pursuant to the terms of such plan) which the Company may at any time or from time to time have in effect for executive employees of the Company or its subsidiaries, Executives participation to be on a basis commensurate with other executive employees considering their respective responsibilities and compensation. Executive shall also be entitled to be reimbursed for all reasonable expenses incurred by him in the performance of his duties hereunder. Executive acknowledges that he has not and shall not participate in the Companys bonus and profit sharing plans and programs.
1.05. Principal Place of Business . The headquarters and principal place of business of the Company is located in Murrysville, Pennsylvania. Executives principal place of business will be at his home in Marco Island, Florida or such other location as Executive may designate. During the summer, early fall and late spring Executive also maintains an office at his home in Export, PA. The Company will not maintain an office for Executive at its headquarters but will reimburse Executive for all reasonable out-of-pocket expenses in maintaining his office at his homes or such other location as he may direct.
ARTICLE II
TERMINATION
2.01. Illness, Incapacity . If, during the Term of Executives employment hereunder, the Board of Directors of the Company shall determine that Executive shall be prevented from effectively performing all his duties hereunder by reason of illness or disability and such failure so to perform shall have continued for a period of not less than three months, then the Company may, by written notice to Executive, terminate Executives employment hereunder effective at any time after such three month period. Upon delivery to Executive of such notice, together with payment of any salary accrued under Section 1.03 hereof, Executives employment and all obligations of the Company under Article I hereof shall forthwith terminate. The obligations of Executive under Article IV hereof shall continue notwithstanding termination of Executives employment pursuant to this Section 2.01.
2.02. Death . If Executive dies during the Term of his employment hereunder, Executives employment hereunder shall terminate and all obligations of the Company hereunder, other than any obligations with respect to the payment of accrued and unpaid salary, shall terminate.
-2-
2.03. Company Termination . (a) For Cause . In the event that, in the reasonable judgment of the Board of Directors of the Company, Executive shall have (a) been guilty of any act of dishonesty material with respect to the Company, (b) been convicted of a crime involving moral turpitude or (c) intentionally disregarded the provisions of this Agreement or the express instructions of the Board of Directors of the Company with respect to matters of policy continuing (in the case of clause (c)) for a period of not less than thirty (30) days after notice of such disregard, the Company may terminate this Agreement effective at such date as it shall specify in a written notice to Executive. Any such termination by the Company shall be deemed to be termination for cause. Upon delivery to Executive of such notice of termination, together with payment of any salary accrued under Section 1.03 hereof, Executives employment and all obligations of the Company under Article I hereof shall forthwith terminate. The obligations of Executive under Article IV hereof shall continue notwithstanding termination of Executives employment pursuant to this Section 2.03(a).
(b) Without Cause . Executives employment hereunder may be terminated at any time by the Company without cause if the Board of Directors of the Company, by resolution duly adopted by the Board, so determines. The obligations of Executive under Article IV hereof shall continue notwithstanding termination of Executives employment pursuant to this Section 2.03(b).
2.04. Executive Termination . Executive agrees to give the Company ninety (90) days prior written notice of the termination of his employment with the Company. In the event Executive has terminated his employment with the Company because, in his reasonable judgment, there has been: (a) a material downgrading in Executives duties, titles or responsibilities, (b) a change in the Companys principal office to a location not within 15 miles of its present location, (c) any significant and prolonged increase in the traveling requirements applicable to the discharge of Executives responsibilities or (d) any other material adverse change in working conditions, responsibilities or prestige, Executive shall be entitled to the compensation provided for in Section 2.05 upon such termination. The obligations of Executive under Article IV hereof shall continue notwithstanding termination of Executives employment pursuant to this Section 2.04.
2.05. Termination Payments . If the Company terminates Executives employment without cause pursuant to Section 2.03(b) or Executive terminates his employment pursuant to Section 2.04, Executive shall be paid an amount equal to the Base Salary then in effect, such payment to be made in a lump sum on the first business day following the six month anniversary of the termination of Executives employment.
2.06. Termination Payments After Certain Business Combinations . If Executive or the Company (except pursuant to Section 2.03(a)) terminates this Agreement during the Term upon or after the occurrence of a Business Combination not approved by a majority of Disinterested Directors then in office, as those terms are defined in Article Ninth of the Companys Certificate of Incorporation, Executive shall be paid an amount equal to three times the Base Salary then in effect, such payment to be made in a lump sum on the first business day following the six month anniversary of the termination of Executives employment. Notwithstanding the foregoing sentence, in the event that any amount or benefit paid or distributed to the Executive pursuant to this Section 2.06, taken together with any amounts or benefits otherwise paid or distributed to the Executive by the Company, would be an excess parachute payment as defined in Section 280G of the Internal Revenue Code of 1986, as amended, (the Code ) and would thereby subject the Executive to the tax ( Excise Tax ) imposed under Section 4999 of the Code (or any
-3-
similar tax that may hereafter be imposed), the provisions of the following sentence shall apply to determine the amounts payable to the Executive pursuant to this Agreement. If (A) the aggregate value of the amounts to be paid or provided to the Executive under Section 2.06 of this Agreement and any other plan, agreement or arrangement with the Company exceeds the amount which can be paid to the Executive without the Executive incurring an Excise Tax and (B) the Executive would receive a greater net-after-tax amount (taking into account all applicable taxes payable by the Executive, including any Excise Tax) by applying the limitation contained in this sentence, then such amounts payable to the Executive under this Section 2.06 shall be reduced (but not below zero) to the maximum amount which may be paid hereunder without the Executive becoming subject to such an Excise Tax.
ARTICLE III
EXECUTIVES ACKNOWLEDGMENTS
Executive recognizes and acknowledges that: (a) in the course of Executives employment by the Company it will be necessary for Executive to acquire information which could include, in whole or in part, information concerning the Companys sales, sales volume, sales methods, sales proposals, customers and prospective customers, identity of customers and prospective customers, identity of key purchasing personnel in the employ of customers and prospective customers, amount or kind of customers purchases from the Company, the Companys sources of supply, the Companys computer programs, system documentation, special hardware, product hardware, related software development, the Companys manuals, formulae, processes, methods, machines, compositions, ideas, improvements, inventions or other confidential or proprietary information belonging to the Company or relating to the Companys affairs (collectively referred to herein as the Confidential Information ); (b) the Confidential Information is the property of the Company; (c) the use, misappropriation or disclosure of the Confidential Information would constitute a breach of trust and could cause irreparable injury to the Company; and (d) it is essential to the protection of the Companys good will and to the maintenance of the Companys competitive position that the Confidential Information be kept secret and that Executive not disclose the Confidential Information to others or use the Confidential Information to Executives own advantage or the advantage of others. For purposes of this Agreement, Confidential Information shall not include any information that is in the public domain, so long as such information is not in the public domain as a result of any action or inaction by Executive which would constitute a violation of this Agreement or the Companys policies with respect to such information.
Executive further recognizes and acknowledges that it is essential for the proper protection of the business of the Company that Executive be restrained, but only to the extent hereinafter provided (a) from soliciting or inducing any employee of the Company to leave the employ of the Company, (b) from hiring or attempting to hire any employee of the Company, (c) from soliciting the trade of or trading with the customers and suppliers of the Company for any business purpose, and (d) from competing against the Company for a reasonable period following the termination of Executives employment with the Company.
Executive further recognizes and understands that his duties at the Company may include the preparation of materials, including written or graphic materials, and that any such materials conceived or written by him shall be done as work made for hire as defined and used in the Copyright Act of 1976, 17 USC § 1 et seq . In the event of publication of such materials, Executive understands that since the work is a work made for hire, the Company will solely retain and own all rights in said materials, including right of copyright, and that the Company may, at its discretion, on a case-by-case basis, grant Executive by-line credit on such materials as the Company may deem appropriate.
-4-
ARTICLE IV
EXECUTIVES COVENANTS AND AGREEMENTS
4.01. Non-Disclosure of Confidential Information . Executive agrees to hold and safeguard the Confidential Information in trust for the Company, its successors and assigns and agrees that he shall not, without the prior written consent of the Company, misappropriate or disclose or make available to anyone for use outside the Companys organization at any time, either during his employment with the Company or subsequent to the termination of his employment with the Company for any reason, including without limitation termination by the Company for cause or without cause, any of the Confidential Information, whether or not developed by Executive, except as required in the performance of Executives duties to the Company or as otherwise required by law or legal process.
4.02. Disclosure of Works and Inventions/Assignment of Patents and Other Rights . (a) Executive shall disclose promptly to the Company or its nominee any and all works, inventions, discoveries and improvements authored, conceived or made by Executive during the period of employment and related to the business or activities of the Company, and hereby assigns and agrees to assign all his interest therein to the Company or its nominee. Whenever requested to do so by the Company, Executive shall execute any and all applications, assignments or other instruments which the Company shall deem necessary to apply for and obtain Letters Patent or Copyrights of the United States or any foreign country or to otherwise protect the Companys interest therein. Such obligations shall continue beyond the termination of employment with respect to works, inventions, discoveries and improvements authored, conceived or made by Executive during the period of employment, and shall be binding upon Executives assigns, executors, administrators and other legal representatives.
(b) Executive agrees that in the event of publication by Executive of written or graphic materials in the course of performing his duties under this Agreement, the Company will retain and own all rights in said materials, including right of copyright.
4.03. Duties . Executive agrees to be a loyal employee of the Company during the Term. Executive agrees to devote his best efforts to the performance of his duties for the Company, to give proper time and attention to furthering the Companys business, and to comply with all rules, regulations and instruments established or issued by the Company, in each case during the Term. Executive shall devote such of his working time as shall be necessary for the performance of his duties hereunder, but he shall not be required to devote more than two-thirds of his working time thereto. Executive further agrees that during the Term of this Agreement, Executive shall not, directly or indirectly, engage in any business which would detract from Executives ability to apply his best efforts to the performance of his duties hereunder. Executive also agrees that he shall not usurp any corporate opportunities of the Company.
4.04. Return of Materials . Upon the termination of Executives employment with the Company for any reason, including without limitation termination by the Company for cause or without cause, Executive shall promptly deliver to the Company all correspondence, drawings, blueprints, manuals, letters, notes, notebooks, reports, flow-charts, programs, proposals and any documents concerning the Companys customers or concerning products or processes used by the Company and, without limiting the foregoing, will promptly deliver to the Company any and all other documents or materials containing or constituting Confidential Information.
-5-
4.05. Restrictions on Competition . Executive covenants and agrees that during the period of Executives employment hereunder plus a period of three years following the termination of Executives employment, including without limitation termination by the Company for cause or without cause, Executive shall not, in the United States of America or in any other country of the world in which the Company has done business at any time during the last three years prior to termination of Executives employment with the Company, engage, directly or indirectly, whether as principal or as agent, officer, director, employee, consultant, shareholder, or otherwise, alone or in association with any other person, corporation or other entity, in any Competing Business. For purposes of this Agreement, the term Competing Business shall mean and include any person, corporation or other entity which develops, manufactures, sells or markets or attempts to develop, manufacture, sell or market any product or services which are the same as or similar to the products and services sold by the Company at any time and from time to time during the last three years prior to the termination of Executives employment hereunder; provided , however , that for purposes of determining what constitutes a Competing Business there shall not be included (x) any product or service of any entity which product or service Executive determines is not material to the business or prospects of the Company and which product or service the Companys Board, having been requested to do so by Executive, also so determines; or (y) any product or service of any entity so long as the Executive and such entity can demonstrate to the reasonable satisfaction of the Company that Executive is and will continue to be effectively isolated from and not participate in the development, manufacture, sale or marketing of such product or service, but only so long as Executive is effectively so isolated and does not so participate.
4.06. Non-Solicitation of Customers and Suppliers . Executive agrees that during his employment with the Company he shall not, directly or indirectly, solicit the trade of, or trade with, any customer, prospective customer, supplier, or prospective supplier of the Company for any business purpose other than for the benefit of the Company. Executive further agrees that for three years following termination of his employment with the Company, including without limitation termination by the Company for cause or without cause, Executive shall not, directly or indirectly, solicit the trade of, or trade with, any customers or suppliers, or prospective customers or suppliers, of the Company.
4.07. Non-Solicitation of Employees . Executive agrees that, during his employment with the Company and for three years following termination of Executives employment with the Company, including without limitation termination by the Company for cause or without cause, Executive shall not, directly or indirectly, solicit or induce, or attempt to solicit or induce, any employee of the Company to leave the Company for any reason whatsoever, or hire any employee of the Company.
ARTICLE V
EXECUTIVES REPRESENTATIONS AND WARRANTIES
5.01. No Prior Agreements . Executive represents and warrants that he is not a party to or otherwise subject to or bound by the terms of any contract, agreement or understanding which in any manner would limit or otherwise affect his ability to perform his obligations hereunder, including without limitation any contract, agreement or understanding containing terms and provisions similar in any manner to those contained in Article IV hereof. Executive further represents and warrants that his employment with the Company will not require him to disclose or use any confidential information belonging to prior employers or other persons or entities.
-6-
5.02. Executives Abilities . Executive represents that his experience and capabilities are such that the provisions of Article IV will not prevent him from earning his livelihood, and acknowledges that it would cause the Company serious and irreparable injury and cost if Executive were to use his ability and knowledge in competition with the Company or to otherwise breach the obligations contained in Article IV.
5.03. Remedies . In the event of a breach by Executive of the terms of this Agreement, the Company shall be entitled, if it shall so elect, to institute legal proceedings to obtain damages for any such breach, or to enforce the specific performance of this Agreement by Executive and to enjoin Executive from any further violation of this Agreement and to exercise such remedies cumulatively or in conjunction with all other rights and remedies provided by law. Executive acknowledges, however, that the remedies at law for any breach by him of the provisions of this Agreement may be inadequate and that the Company shall be entitled to injunctive relief against him in the event of any breach.
ARTICLE VI
MISCELLANEOUS
6.01. Authorization to Modify Restrictions . It is the intention of the parties that the provisions of Article IV hereof shall be enforceable to the fullest extent permissible under applicable law, but that the unenforceability (or modification to conform to such law) of any provision or provisions hereof shall not render unenforceable, or impair, the remainder thereof. If any provision or provisions hereof shall be deemed invalid or unenforceable, either in whole or in part, this Agreement shall be deemed amended to delete or modify, as necessary, the offending provision or provisions and to alter the bounds thereof in order to render it valid and enforceable.
6.02. Tolling Period . The non-competition, non-disclosure and non-solicitation obligations contained in Article IV hereof shall be extended by the length of time during which Executive shall have been in breach of any of the provisions of such Article IV.
6.03. Entire Agreement . This Agreement represents the entire agreement of the parties with respect to the employment of Executive by the Company and may be amended only by a writing signed by each of them.
6.04. Governing Law . This Agreement shall be governed by and construed in accordance with the laws of the Commonwealth of Pennsylvania.
6.05. Consent to Jurisdiction; Venue . Executive hereby irrevocably submits to the personal jurisdiction of the United States District Court for the Western District of Pennsylvania or the Court of Common Pleas of Allegheny County, Pennsylvania in any action or proceeding arising out of or relating to this Agreement, and Executive hereby irrevocably agrees that all claims in respect of any such action or proceeding may be heard and determined in either such court. Executive hereby irrevocably waives any objection which he now or hereafter may have to the laying of venue of any action or proceeding arising out of or relating to this Agreement brought in the United States District Court for the Western District of Pennsylvania or the Court of Common Pleas of Allegheny County, Pennsylvania and any objection on the ground that any such action or proceeding in either of such Courts
-7-
has been brought in an inconvenient forum. Nothing in this Section 6.05 shall affect the right of the Company to bring any action or proceeding against Executive or his property in the courts of other jurisdictions where Executive resides or has his principal place of business or where such property is located.
6.06. Service of Process . Executive hereby irrevocably consents to the service of any summons and complaint and any other process which may be served in any action or proceeding arising out of or related to this Agreement brought in the United States District Court for the Western District of Pennsylvania or the Court of Common Pleas of Allegheny County by the mailing by certified or registered mail of copies of such process to Executive at his address as set forth on the signature page hereof.
6.07. Remedies . If the Company finally prevails in a proceeding for damages or injunctive relief, the Company, in addition to other relief, shall be entitled to reasonable attorneys fees, costs and the expenses of litigation incurred by the Company in securing the relief granted by the Court.
6.08. Agreement Binding . The obligations of Executive under this Agreement shall continue after the termination of his employment with the Company for any reason, with or without cause, and shall be binding on, and inure to the benefit of, his heirs, executors, legal representatives and assigns. If Executive should die while any amounts are still payable to him hereunder, all such amounts, unless otherwise provided herein, shall be paid in accordance with the terms of this Agreement to Executives devisee, legatee or designee or, if there be no such designee, to the Executives estate. This Agreement shall be binding upon and inure to the benefit of any successors or assigns of the Company.
6.09. Counterparts, Section Headings . This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original, but all of which together shall constitute one and the same instrument. The section headings of this Agreement are for convenience of reference only and shall not affect the construction or interpretation of any of the provisions hereof.
6.10. Notices . All notices, requests, demands and other communications hereunder shall be in writing and shall be deemed to have been duly given if (a) hand delivered or (b) mailed, registered mail, first class postage paid, return receipt requested, or (c) sent via overnight delivery service or courier, delivery acknowledgment requested, or (d) via any other delivery service with proof of delivery:
if to the Company:
Respironics, Inc.
1010 Murry Ridge Lane
Murrysville, PA 15668
if to Executive, at the address set forth below
or to such other address or to such other person as either party hereto shall have last designated by notice to the other party.
6.11. Section 409A . Within the time period permitted by the applicable Treasury Regulations, the Company may, in consultation with the Executive, modify the
-8-
Agreement, in the least restrictive manner necessary and without any diminution in the value of the payments to the Executive, in order to cause the provisions of the Agreement to comply with the requirements of Section 409A of the Code, so as to avoid the imposition of taxes and penalties on the Executive pursuant to Section 409A of the Code.
Executive acknowledges that he has read and understands the foregoing provisions and that such provisions are reasonable and enforceable.
IN WITNESS WHEREOF, the parties hereto have executed this Agreement or caused this Agreement to be executed the day and year first above written.
|
/s/ Gerald E. McGinnis |
||
|
Gerald E. McGinnis |
||
| Address: |
1031 Pettit Court Marco Island, FL 34145 |
|
| RESPIRONICS, INC. | ||
| By: |
/s/ William R. Wilson |
|
| Title: | Chief Human Resources Officer | |
-9-
Exhibit 10.61
AMENDED AND RESTATED EMPLOYMENT AGREEMENT
THIS AGREEMENT (the Agreement ), made as of November 13, 2007, by and between RESPIRONICS, INC., a Delaware corporation (the Company ) and Craig Reynolds ( Executive ). If future benefits provided to Executive Vice Presidents, Senior Vice Presidents or the President (other than base salary) become more favorable than those contained herein, Executive will receive the benefit of those changes.
W I T N E S S E T H :
WHEREAS, the Company is engaged in the business of the design, development, manufacture, marketing and sale principally of respiratory and other medical equipment;
WHEREAS, Executive possesses valuable knowledge and skills that will contribute to the successful operation of the Companys business;
WHEREAS, Executive and the Company are currently parties to an Employment Agreement executed on or about November 11, 1997 (as amended, from time to time prior to the date of this Agreement, the Original Agreement );
WHEREAS, pursuant to the Original Agreement, as partial consideration for Executives agreement to forego the exercise of certain rights worth One Million, Seven Hundred Thousand Dollars ($1,700,000) set forth in the Original Agreement and remain in the employ of the Company in accordance with the terms and conditions of the Original Agreement, the Company agreed on August 16, 2000 to (i) pay Executive certain additional amounts upon termination or expiration of the Original Agreement, and (ii) guaranty a $300,000 loan obtained by Executive, to reimburse Executive for interest payable on such loan and to gross-up one time Executives income to account for any additional federal and state income tax payable by Executive as a result of the Companys reimbursement of Executive for interest payable on such loan;
WHEREAS, Executive and the Company desire to amend and restate the Original Agreement as herein set forth;
WHEREAS, the Company and Executive have agreed to execute and deliver this Agreement in consideration, among other things, of (i) the access Executive will have to confidential or proprietary information of the Company, (ii) the access Executive will have to confidential or proprietary information to be acquired hereafter by the Company, and (iii) Executives receipt of compensation from time to time by the Company; and
WHEREAS, the Company desires to retain the services of Executive, and Executive is willing to accept employment with the Company, subject to the terms and conditions hereinafter set forth.
NOW, THEREFORE, intending to be legally bound, the Company agrees to employ Executive, and Executive hereby agrees to be employed by the Company, upon the following terms and conditions:
ARTICLE I
EMPLOYMENT
1.01. Office . Executive will be employed as Executive Vice President and Chief Operating Officer of the Company, having such duties and responsibilities as are commensurate with such position and title. Executive shall report to the President and Chief Executive Officer of the Company and shall also perform such other duties unrelated to his title and position as may be mutually agreed upon by Executive and the Company. (Such duties and responsibilities shall hereinafter be referred to as Executives Services.) In such capacity or capacities Executive shall use his best energies or abilities in the performance of his Services hereunder and as prescribed in the By-Laws of the Company.
1.02. Term . Subject to the terms and provisions of Article II hereof, Executive shall be employed by the Company for a period of three years (the Term ), commencing on the date of this Agreement. Subject to the terms and provisions of Article II hereof, the Term shall automatically be extended for additional three year periods unless, not less than ninety (90) days prior to the expiration of the first year of the then-current Term, either Executive or the Company shall advise the other that the Term will not be further extended. Term shall also include any extension or renewals of the original Term, but shall not include the Extended Employment Period, as defined in Section 2.08.
1.03. Base Salary . Compensation shall be paid to Executive by the Company at the rate of $529,876.00 per annum (the Base Salary ), payable bi-weekly. The Base Salary to be paid to Executive may be adjusted upward (but not downward) by the Board of Directors of the Company at any time (but not less frequently than annually) based upon Executives contribution to the success of the Company and on such other factors as the Board of Directors of the Company shall deem appropriate.
1.04. Executive Benefits . At all times during the Term, Executive shall have the right to participate in and receive benefits under and in accordance with the then-current provisions of all incentive, profit sharing, retirement, stock option or purchase plans, life, health and accident insurance, hospitalization and other incentive and benefit plans or programs (except for any such plan in which Executive may not participate pursuant to the terms of such plan or Executives geographic location) which the Company may at any time or from time to time have in effect for executive employees of the Company or its subsidiaries, Executives participation to be on a basis commensurate with other executive employees considering their respective responsibilities and compensation. Prior service of Executive with the Company, Healthdyne Technologies, Inc. ( Healthdyne ) or a Healthdyne subsidiary (including service with predecessor entities to the extent recognized under analogous Healthdyne benefit plans) shall be counted in determining eligibility to participate in benefit plans and programs applicable to Executive hereunder and for purposes of vesting. Executive shall also be entitled to be reimbursed for all reasonable expenses incurred by him in the performance of his Services hereunder.
1.05. Principal Place of Business . The headquarters and principal place of business of the Company is located in Pittsburgh, Pennsylvania. For Executives convenience, Executives principal place of business will be in Kennesaw, Georgia, and he will reside within a reasonable distance thereof.
-2-
ARTICLE II
SEPARATION OF SERVICE
2.01. Illness, Incapacity . If, during the Term, the Board of Directors of the Company shall determine that Executive shall be prevented from effectively performing all his Services hereunder by reason of illness or disability, confirmed by a physician mutually acceptable to Executive and the Company, and such failure so to perform shall have continued for a period of not less than six months, then the Company may, by written notice to Executive, separate the Executive from performance of Services hereunder (such separation shall hereinafter be referred to as Separation of Service) effective at any time after such six month period. Upon delivery to Executive of such notice, together with payment of any salary accrued and unpaid under Section 1.03 hereof, Executives Services and all obligations of the Company under Article I (except any obligation for vested benefits) hereof shall forthwith terminate. The obligations of Executive under Articles III and IV (but only Sections 4.01-4.04, 4.06, and 4.07) hereof, and the Companys obligations under Section 2.08 hereof, shall continue notwithstanding Executives Separation of Service pursuant to this Section 2.01.
2.02. Death . If Executive dies during the Term, Executives Services shall terminate and all obligations of the Company hereunder, other than any obligations with respect to the payment of accrued, unpaid salary and vested benefits, shall terminate; provided , however , that the Companys obligations under Section 2.08 hereof shall continue notwithstanding Executives Separation of Service pursuant to this Section 2.02.
2.03. Separation of Service by Company . (a) For Cause . In the event that, in the reasonable judgment of the Board of Directors of the Company after a meeting at which Executive is given reasonable notice and afforded an opportunity to attend, be heard and be accompanied by a lawyer, Executive shall have (a) been guilty of any act of dishonesty material with respect to the Company, (b) been convicted of a crime involving moral turpitude which affects Executives ability to perform his Services under this Agreement or which materially adversely affects the Company or (c) intentionally disregarded express instructions of the Board of Directors of the Company with respect to material matters of policy continuing (in the case of clause (c)) for a period of not less than thirty (30) days after notice of such disregard, the Company may terminate Executives Services effective at such date as it shall specify in a written notice to Executive (other than any such disregard resulting from incapacity due to physical or mental illness or following Executives delivery of a notice of Separation of Service pursuant to Section 2.04(a)). Any such Separation of Service by the Company shall be deemed to be for cause. During the Change of Control Protection Period (as defined below), (1) for purposes of this Section 2.03(a), no act, or failure to act, on the part of Executive shall be considered intentional unless it is done, or omitted to be done, by Executive in bad faith or without reasonable belief that Executives action or omission was in the best interests of the Company, (2) any act, or failure to act, based upon authority (x) given pursuant to a resolution duly adopted by the Board of Directors, or if the Company is not the ultimate parent corporation and is not publicly-traded, the board of directors of the ultimate parent of the Company (the Applicable Board ), (y) upon the instructions of the President of the Company or (z) based upon the advice of counsel for the Company shall be conclusively presumed to be done, or omitted to be done, by Executive in good faith and in the best interests of the Company and (3) the Separation of Service of Executive shall not be deemed to be for cause unless and until there shall have been delivered to Executive a copy of a resolution duly adopted by the affirmative vote of not less than three-quarters of the independent directors of the Applicable Board (excluding Executive, if Executive is a member of the
-3-
Applicable Board) at a meeting of the Applicable Board called and held for such purpose (after reasonable notice is provided to Executive and Executive is given an opportunity, together with counsel for Executive, to be heard before the Applicable Board), finding that, in the good faith opinion of the Applicable Board, Executive is guilty of the conduct described in Section 2.03, and specifying the particulars thereof in detail. Upon delivery to Executive of notice of Separation of Service in accordance with the procedural requirements of this Section 2.03, together with payment of any salary accrued and unpaid under Section 1.03 hereof and vested benefits for which the Company is obligated, Executives Services and all obligations of the Company under Article I hereof shall forthwith terminate. The obligations of Executive under Articles III and IV hereof, and the Companys obligations under Section 2.08 hereof, shall continue notwithstanding Executives Separation of Service pursuant to this Section 2.03(a). Change of Control Protection Period means the period commencing upon the occurrence of a Change of Control (as defined in Section 2.06(b)) through and including the twenty-four (24) month anniversary of the Change of Control.
(b) Without Cause . Executives Services hereunder may be terminated at any time by the Company without cause if the Board of Directors of the Company, by resolution duly adopted by the Board, so determines. Except as set forth in Sections 2.05 and 2.06 hereof, all obligations of the Company under Article I cease upon Separation of Service pursuant to this Section 2.03 (b) (except for accrued and unpaid salary and any obligation for vested benefits). The obligations of Executive under Articles III and IV hereof, and the Companys obligations under Section 2.08 hereof, shall continue notwithstanding Executives Separation of Service pursuant to this Section 2.03(b).
2.04. Separation of Service by Executive . (a) Except during the Change of Control Protection Period, Executive agrees to give the Company ninety (90) days prior written notice of the termination of his Services with the Company. Simultaneously with such notice, except during the Change of Control Protection Period, Executive shall inform the Company in writing as to his employment plans following the Separation of Service with the Company. In the event Executive has terminated his Services with the Company because there has been: (i) a material downgrading in Executives duties, titles or responsibilities for the Company or a reduction in his annual target incentive of 10% or more, (ii) a change in Executives principal place of business to a location not within 30 miles of its present location, (iii) any significant and prolonged increase in the traveling requirements applicable to the discharge of Executives responsibilities, (iv) he has been removed from or not reelected to the Board of Directors of the Company, (v) any breach of the Company of its duties or obligations pursuant to this Agreement which has not been cured within thirty (30) days after notice of such breach, (vi) any failure of any successors to the Company after a Change of Control (as defined herein) to assume the obligations of the Company hereunder, (vii) as a condition to any renewal or extension of this Agreement, the imposition by the Company of any adverse change in any material term or provision of this Agreement, (viii) any other material adverse change in working conditions, responsibilities or prestige, (ix) during the Change of Control Protection Period only, the failure by the Company to continue to provide Executive with employee benefits substantially similar to those enjoyed by him immediately prior to the Change of Control or the taking of any action by the Company which would directly or indirectly materially reduce any of such benefits or deprive Executive of any material fringe benefit enjoyed by the Executive immediately prior to the Change of Control or (x) during the Change of Control
-4-
Protection Period only, notice by the Company that it will not extend the Term pursuant to Section 1.02; then, in the case of any of the events described in clauses (i) through (x), Executive shall be entitled to the compensation provided for in Section 2.05 upon such Separation of Service. For purposes of this Section 2.04(a), during the Change of Control Protection Period, any good faith determination made by Executive regarding the occurrence of any of the events described in clauses (i) through (x) of this Section 2.04(a) shall be presumed correct unless the Company can prove otherwise. In addition, for purposes of this Section 2.04(a), the Executives mental or physical incapacity following the occurrence of an event described above in clauses (i) through (x) shall not affect the Executives ability to terminate his Services for any of the reasons described in clauses (i) through (x) of this Section 2.04(a).
(b) Without prejudice to Executives rights under Section 2.04(a), all obligations of the Company under Article I shall cease upon Executives Separation of Service pursuant to this Section 2.04, except for the payment of any salary accrued and unpaid under Section 1.03 hereof and any obligation for vested benefits. The obligations of Executive under Articles III and IV hereof, and the Companys obligations under Section 2.08 hereof, shall continue notwithstanding Executives Separation of Service pursuant to this Section 2.04.
2.05. Separation of Service Payments Discharge Without Cause; Separation of Service Pursuant to Section 2.04(a) . If (a) the Company terminates Executives Services without cause pursuant to Section 2.03(b) or (b) Executive terminates his Services pursuant to Section 2.04(a) (either of clauses (a) and (b), a Qualifying Separation of Service ), Executive shall be entitled to a lump sum payment in an amount equal to (i) his W-2 wages as required to be reported to the Internal Revenue Service (IRS) in Box 1 on Executives W-2 Wage and Tax Statement during the immediately preceding three completed calendar years, plus (ii) the aggregate amount of Executives car allowance (as in effect immediately prior to the Separation of Service (without giving effect to any reduction)) for a thirty-six month period, such amount to be paid within sixty (60) days of Executives Separation of Service; provided, however, that, subject to the immediately following sentence, with respect to clause (ii) only, such amounts shall be payable upon the later of (i) the date specified in this Section 2.05 and (ii) January 1, 2008. Notwithstanding the immediately preceding sentence, in the event that the Executive is a specified employee within the meaning of Section 409A of the Internal Revenue Code of 1986, as amended (the Code ) (as determined in accordance with the methodology established by the Company as in effect on the date of Separation of Service), amounts that would otherwise be payable under this Section 2.05 during the six-month period immediately following the date of Separation of Service shall instead be paid on the first business day after the date that is six months following the Executives separation from service within the meaning of Section 409A of the Code. In addition, for three years after the Executives date of Separation of Service, the Company shall continue to provide health insurance coverage (which includes dental coverage) to the Executive at a level substantially similar to the health insurance benefits enjoyed by Executive prior to his Separation of Service (without giving effect to any reduction); provided , however , that the health insurance coverage provided during such period shall be provided in such a manner that such benefits (and the costs and premiums thereof) are excluded from the Executives income for federal income tax purposes (if the Company reasonably determines that providing continued coverage under one or more of its health care benefit plans contemplated herein could be taxable to the Executive, the Company shall provide such benefits at the level required hereby through the purchase of individual insurance coverage). For the avoidance of doubt, this Section 2.05 shall apply to a Qualifying Separation of Service prior to, upon the occurrence of, or following a Change of Control and the Company acknowledges that Executive will be entitled to the payments contemplated by this Section 2.05 if Executive experiences a Qualifying Separation of Service prior to, upon the occurrence of, or following a Change of Control. In addition, for the avoidance of doubt, in the event that the Company makes full payment of all the
-5-
amounts contemplated by this Section 2.05, the Company will have no obligation to make any payments contemplated by Section 2.06(a). Executive has no duty to mitigate the payments contemplated by this Section 2.05 and these payments will not be reduced in any way should Executive obtain other employment during the period in which payments are being made.
2.06. Separation of Service Payments After Certain Business Combinations . (a) If Executive or the Company (except pursuant to Section 2.03(a) hereof) terminates Executives Services during the Term upon or after the occurrence of a Business Combination not approved by a majority of Disinterested Directors then in office, as those terms are defined in Article Ninth of the Companys Certificate of Incorporation, Executive shall be paid an amount equal to (i) three times Executives average W-2 wages as required to be reported to the IRS in Box 1 on Executives W-2 Wage and Tax Statement during the immediately preceding three completed calendar years, plus (ii) the aggregate amount of Executives car allowance (as in effect immediately prior to the Separation of Service (without giving effect to any reduction)) for a thirty-six month period, such payment to be made in a lump sum within sixty (60) days of Executives Separation of Service. Notwithstanding the immediately preceding sentence, in the event that the Executive is a specified employee within the meaning of Section 409A of the Code (as determined in accordance with the methodology established by the Company as in effect on the date of Separation of Service), amounts that would otherwise be payable under this Section 2.06(a) during the six-month period immediately following the date of Executives Separation of Service shall instead be paid on the first business day after the date that is six months following the Executives separation from service within the meaning of Section 409A of the Code. In addition, for three years after the Executives date of Separation of Service, the Company shall continue to provide health insurance coverage (which includes dental coverage) to the Executive at a level substantially similar to the health insurance benefits enjoyed by Executive prior to his Separation of Service (without giving effect to any reduction); provided , however , that the health insurance coverage provided during such period shall be provided in such a manner that such benefits (and the costs and premiums thereof) are excluded from the Executives income for federal income tax purposes (if the Company reasonably determines that providing continued coverage under one or more of its health care benefit plans contemplated herein could be taxable to the Executive, the Company shall provide such benefits at the level required hereby through the purchase of individual insurance coverage). For the avoidance of doubt, in the event that the Company makes full payment of all the amounts contemplated by this Section 2.06(a), the Company will have no obligation to make any payments contemplated by Section 2.05. Executive has no duty to mitigate the payments contemplated by this Section 2.06(a) and these payments will not be reduced in any way should Executive obtain other employment during the period in which payments are being made.
(b) As used herein a Change of Control shall be deemed to have occurred if (a) there shall be consummated (i) any consolidation or merger of the Company in which the Company is not the continuing or surviving corporation or pursuant to which shares of the Companys common stock would be converted into cash, securities or other property, other than a merger of the Company in which the holders of the Companys common stock immediately prior to the merger have the same proportionate ownership of common stock of the surviving corporation immediately after the merger, or (ii) any sale, lease, exchange or other transfer (in one transaction or a series of related transactions) of all, or substantially all, of the assets of the Company, or (b) the stockholders of the Company approve any plan or proposal for the liquidation or dissolution of the Company, or (c) any person (as such term is used in Sections 13(d) and 14(d)(2) of the Securities Exchange Act of 1934, as amended (the Exchange Act )), shall become the beneficial
-6-
owner (within the meaning of Rule 13d-3 under the Exchange Act) of 30% of the Companys outstanding common stock, or (d) during any period of two consecutive years, individuals who at the beginning of such period constitute the entire Board of Directors of the Company shall cease for any reason to constitute a majority thereof unless the election, or the nomination for election by the Companys stockholders, of each new director was approved by a vote of at least two-thirds of the directors then still in office who were directors at the beginning of the period; provided , however , that, in the absence of a majority vote of the directors to the contrary, the sale, lease, exchange or other disposition (in one transaction or a series of related transactions) of less than 70% of the total fair market value of all of the assets of the Company immediately prior to such transaction or transactions shall not be deemed to be a Change in Control and provided further that the transaction or transactions which involve the sale, lease, exchange or other disposition of 70% or more of the total fair market value of all of the assets of the Company immediately prior to such transaction or transactions shall be deemed to be a Change in Control even if approved by the Board of Directors of the Company.
2.07. Separation of Service Payments Taxes . The parties hereto agree that the Separation of Service payments contemplated by this Article II are reasonable compensation in consideration of the Executives adherence to the terms of Article IV hereof. Neither party shall contest the payment of such benefits as constituting an excess parachute payment within the meaning of Section 280G(b)(I) of the Code. In the event that Executive becomes entitled to the Separation of Service payments contemplated by this Article II and Executive becomes subject to the tax imposed by Section 4999 of the Code (the Excise Tax ) as a result of the Separation of Service payments and any other benefits or payments required to be taken into account under Code Section 280G(b)(2) ( Parachute Payments ), the Company shall pay to Executive an additional amount (the Gross-Up Payment ) such that the net amount retained by Executive, after deduction of any Excise Tax on the Parachute Payments and any Federal, state and local income tax and Excise Tax upon the payment provided for by this paragraph, shall be equal to the Parachute Payments determined prior to the application of this paragraph. For purposes of determining the amount of the Parachute Payments, no payments or benefits shall be included if, in the opinion of tax counsel selected by the Companys independent auditors and acceptable to Executive, such payments or benefits (in whole or in part) do not constitute Parachute Payments, or such payments (in whole or in part) represent reasonable compensation for services actually rendered within the meaning of Section 280G(b)(4) of the Code. The value of any non-cash benefits or any deferred payment or benefit shall be determined by the Companys independent auditors. For purposes of determining the amount of the Gross-Up Payment, Executive shall be deemed to pay Federal income taxes at the highest marginal rate of Federal income taxation in the calendar year in which the Gross-Up Payment is to be made and state and local income taxes at the highest marginal rates of taxation in the state and locality of Executives residence on the date of Separation of Service, net of the maximum reduction in Federal income taxes which could be obtained from deduction of such state and local taxes. In the event that the Excise Tax payable by Executive is subsequently determined to be less than the amount taken into account hereunder at the time of Executives Separation of Service, Executive shall repay to the Company at the time that the amount of such reduction in Excise Tax is finally determined the portion of the Gross-Up Payment attributable to such reduction plus interest on the amount of such repayment at the rate provided for in Section 1274(b)(2)(B) of the Code ( Repayment Amount ). In the event that the Excise Tax payable by Executive is determined to exceed the amount taken into account thereunder at the time of the Executives Separation of Service (including by reason of any payment the existence or amount of which cannot be determined at the time of the Gross-Up Payment), the Company shall make an additional Gross-Up Payment in respect of such excess (plus any interest
-7-
payable with respect to such excess) at the time that the amount of such excess is finally determined ( Additional Gross-up ). The obligation to pay any Repayment Amount or Additional Gross-up shall remain in effect under this Agreement for the entire period during which the Executive remains liable for the Excise Tax, including the period during which any applicable statute of limitation remains open. Such Gross-Up Payment and Additional Gross-Up shall be paid at such time as Executive remits payment for Excise Tax to any taxing authority; however, in no event will any Gross-Up Payment or Additional Gross-Up be made later than the end of Executives taxable year in which the related taxes are remitted to the taxing authority.
Section 2.08 Extended Employment Period and Additional Payments Upon Separation of Service or Expiration of the Term . (a) Commencing simultaneously upon the earlier of (i) the expiration of the Term, or (ii) Executives Separation of Service for any reason (including, but not limited to any Separation of Service initiated either by the Company or by the Executive, but excluding a Separation of Service due to the death of Executive in accordance with Section 2.02 hereof) (hereinafter an Extended Employment Event), Executive shall remain in the employ of the Company for the Extended Employment Period (as defined below) in accordance with the terms of this Section 2.08. As used herein, the Extended Employment Period shall mean two (2) years from the Extended Employment Event. At all times during the Extended Employment Period, Executive shall have the right to participate in stock option or purchase plans and health insurance plans as specified in this Section 2.08 hereof and shall have the right to participate in the then current provisions of all life, disability and accident insurance plans or programs (except for any such plan in which Executive may not participate pursuant to the terms of such plan or Executives geographic location) which the Company may at any time or from time to time have in effect for employees of the Company or its subsidiaries.
(b) Upon an Extended Employment Event or upon Executives Separation of Service pursuant to Section 2.02 hereof, the Company shall pay to Executive (or Executives estate or beneficiaries following Executives death) a lump sum amount equal to (i) one hundred and fifty percent (150%) of his Base Salary in effect immediately prior to Executives Extended Employment Event and commencement of the Extended Employment Period (without giving effect to any reduction), plus (ii) the aggregate amount of (x) Executives car allowance (as in effect immediately prior to Executives Extended Employment Event (without giving effect to any reduction)) for a twenty-four month period, (y) an amount equal to two hundred percent (200%) of the Companys matching contributions on behalf of Executive under the Companys Retirement Savings Plan during the last completed fiscal year of the Company immediately prior to Executives Extended Employment Event and commencement of the Extended Employment Period (or, if greater, the last completed fiscal year of the Company preceding a Change of Control) and (z) an amount equal to two hundred percent (200%) of the Companys contributions on behalf of the Executive under the Companys supplemental executive retirement plan during the last completed fiscal year of the Company immediately prior to Executives Extended Employment Event and commencement of the Extended Employment Period (or, if greater, the last completed fiscal year of the Company preceding a Change of Control) (clauses (i) and (ii), (the Additional Payments ). Notwithstanding the immediately preceding sentence, in the event that the Executive is a specified employee within the meaning of Section 409A of the Code (as determined in accordance with the methodology established by the Company as in effect on the date of Executives Extended Employment Event), amounts that would otherwise be payable under this Section 2.08(b) during the six-month period immediately following the Executives Extended Employment Event shall instead be paid on the first business day after the date that is six months following the Executives separation from service within the meaning of Section 409A of the Code. In addition,
-8-
during the Extended Employment Period, the Company shall continue to provide health insurance coverage (which includes dental coverage) to the Executive at a level substantially similar to the health insurance benefits enjoyed by Executive prior to Executives Extended Employment Event (without giving effect to any reduction); provided , however , that such benefits provided during such two-year period shall be provided in such a manner that such benefits (and the costs and premiums thereof) are excluded from the Executives income for federal income tax purposes (if the Company reasonably determines that providing continued coverage under one or more of its welfare benefit plans contemplated herein could be taxable to the Executive, the Company shall provide such benefits at the level required hereby through the purchase of individual insurance coverage). The Company shall withhold all amounts required with respect to the Additional Payments. Executive has no duty to mitigate the payments contemplated by this Section 2.08(b) and these payments will not be reduced in any way should Executive obtain other employment during the period in which payments are being made.
(c) During the Extended Employment Period, Executive shall perform general advisory duties for the Company for a minimum of one (1) eight (8) hour day per calendar month or as mutually agreed upon by Executive and the Company. It is acknowledged and agreed that Executive shall not be an executive officer of the Company during the Extended Employment Period, and shall not be subject to the Companys policy restricting the sale of securities by the Companys officers and employees; provided, however, that Executive shall comply with all trading restrictions as may be applicable under federal and state securities laws. During the Extended Employment Period, Executive will not be required to travel from his place of employment in Kennesaw, Georgia (or such other location as Executive may designate in writing from time to time) on Company business without Executives consent. Executive shall receive the Additional Payments and the benefits provided for in this Section 2.08 during the Extended Employment Period regardless of whether the Company requests Executive to perform advisory services. Executive shall voluntarily resign from the Board of Directors of the Company effective as of the commencement of the Extended Employment Period.
(d) It is the intention of the parties that Executive shall remain an employee of the Company during the Extended Employment Period and that, accordingly, the Company represents and warrants that any and all stock options or awards granted to Executive (collectively, Options) under any stock option plan, stock incentive plan or similar plan or program maintained by the Company or any of its predecessors (collectively, Option Plans) which were outstanding immediately prior to Executives Extended Employment Event and commencement of the Extended Employment Period shall remain in full force and effect during the Extended Employment Period and shall continue to vest and become exercisable during the Extended Employment Period, and that the Options shall be exercisable after the expiration of the Extended Employment Period in accordance with the terms of the respective Option Plans. The Company further represents and warrants that the number of shares of Common Stock covered by the Options and the exercise price thereof shall not be affected by any change in tax treatment of such Options and that such Options shall remain in full force and effect notwithstanding any change in tax treatment of such Options. The Company makes no representation and warranty with respect to the tax treatment of the Options upon the exercise of such Options by Executive; however, the Company agrees that it will at all times recognize and treat Executive as an employee during the term of the Extended Employment Period. The Company agrees that it will take any and all actions necessary to insure that the Option Plans are consistent with the Companys obligations under this Section 2.08, and the Company agrees that no provision of the Option Plans will preclude the Company from meeting its obligations hereunder. For purposes of clarity, any provision in any Option Plan, Option agreement or other agreement
-9-
or document executed by Executive that purports to limit what may be included in the calculation of any payment or benefit due Executive following Executives Separation of Service or the expiration of the Term shall be void in its inception and shall not be effective, including, but not limited to, Section 7 of the Option agreements executed by Executive pursuant to the Companys 2000 and 2006 Option Plans; such Option agreements shall remain in full force and effect and shall be construed as if Section 7 did not appear therein.
(e) If Executives Services are terminated pursuant to Section 2.02 as a result of the death of Executive, or if Executive dies during the Extended Employment Period, then all Options outstanding on the date of Executives death shall immediately vest and shall be exercisable by his estate for the earlier of (i) a period of one (1) year from the date of his death, or (ii) the original maximum term of the Option.
(f) In the event that Executive is entitled to receive monetary benefits upon a Separation of Service in accordance with any of the other Sections of Article II (if applicable), such monetary benefits shall be paid in full as if Executives employment had not been continued for the Extended Employment Period and shall be in addition to the amounts payable to Executive in accordance with this Section 2.08. Amounts payable under this Section 2.08 shall be payable upon the later of (i) the date specified for such payment in this Section 2.08, or (ii) January 1, 2008. If Executive is entitled to continuation of health insurance and other benefits as a result of a Separation of Service (e.g., benefits are continued in accordance with Sections 2.04, 2.05 and/or 2.06 hereof), such continuation shall commence at the end of the Extended Employment Period, it being the intention of the parties that such periods shall run consecutively and that Executive shall receive continuation of benefits under this Section 2.08, followed by continuation of benefits to which Executive may be entitled under Sections 2.04, 2.05 and/or 2.06 hereof, followed by full COBRA benefits. If the Companys COBRA coverage does not allow continuation of benefits in accordance with this Section 2.08, the Company agrees to provide Executive continuation of such benefits for the period of time that would have otherwise been available to Executive, his spouse or dependants under COBRA, e.g., for eighteen (18) months (or, with respect to Executives spouse, in the event that Executive dies during the benefits continuation periods described above, for thirty-six (36) months), commencing at the end of the later of the benefit continuation periods specified above; provided , however , that the health insurance coverage provided during such period shall be provided in such a manner that such benefits (and the costs and premiums thereof) are excluded from the Executives income for federal income tax purposes (if the Company reasonably determines that providing continued coverage under one or more of its health care benefit plans contemplated herein could be taxable to the Executive, the Company shall provide such benefits at the level required hereby through the purchase of individual insurance coverage).
(g) This Section 2.08 shall survive Executives Separation of Service, the expiration of the Term and the termination of this Agreement for any reason. The Company may not terminate Executive during the Extended Employment Period for any reason whatsoever other than upon the death of Executive. In the event that the Company terminates Executive in contravention of the immediately preceding sentence, (A) any Options which were outstanding immediately prior to such termination shall remain in full force and effect for the shorter of (i) the original two year term of the Extended Employment Period, (ii) the original maximum term of the Option, and (iii) ten (10) years from the original Option grant date, (B) any unvested Options held by Executive that would have vested during the original term of the Extended Employment Period shall automatically vest and become fully exercisable, (C) all such Options shall remain exercisable for the shorter of (1) the period of time that the Options would have remained exercisable had
-10-
Executive remained an employee in good standing until the end of the Extended Employment Period, (2) the original maximum term of the Option, and (3) ten (10) years from the original Option grant date, and (D) Executives health insurance coverage shall be continued by the Company for the original term of the Extended Employment Period as set forth in this Section 2.08(b) and (f). Executive may terminate his employment during the Extended Employment Period by giving the Company at least ninety (90) days prior written notice of his intent to terminate the Extended Employment Period; provided that if Executive terminates his employment during the Extended Employment Period, all unvested Options shall terminate upon Executives termination of employment and any vested Options may be exercised in accordance with the terms of the Option Plans. Such termination by Executive shall not affect any other obligation of the Company to Executive in this Agreement. In the event of any conflict between the provisions of this Section 2.08 and the other provisions of this Agreement, the provisions of Section 2.08 shall prevail. For the avoidance of doubt, the payments and benefits contemplated by this Section 2.08 shall be in addition to any payments and benefits contemplated by Sections 2.04, 2.05, 2.06 or 2.07 of this Agreement.
ARTICLE III
EXECUTIVES ACKNOWLEDGMENTS
Executive recognizes and acknowledges that in the course of Executives employment by the Company: (a) he will be privy to certain confidential and proprietary information which constitutes trade secrets as defined in the Uniform Trade Secrets Act and as adopted by the various states (the Act ); and (b) he will be privy to certain other confidential and/or proprietary information that may not constitute trade secrets as defined in the Act.
Executive acknowledges that the Company must protect both above kinds of information from disclosure or misappropriation, and Executive further acknowledges that the processes, machines, technical documentation, computer programs, customer lists, business plans, marketing plans and techniques, pricing data, financial data, marketing programs, customer files, financial institution files, technical expertise and know how, and other information and trade secrets, whether as defined in the Act or which may lie beyond it (collectively the Property ), which have been or will be provided to Executive by the Company, are unique, confidential and proprietary Property of the Company and by the provision of such Property to Executive, the Company is not conveying any ownership or other interest to Executive. Executive acknowledges that such confidential and proprietary information derives independent, actual, and potential commercial value from not being generally, readily ascertainable through independent development and is the subject of efforts by the Company that are reasonable under the circumstances to maintain its secrecy. Property shall not include any information that is in the public domain, so long as such information is not in the public domain as a result of any action or inaction by Executive which would constitute a violation of this Agreement or the Companys policies with respect to such Property. Executive agrees to hold in trust and confidence for the Company and to not to disclose to any third party, without prior written consent of the Company, said Property and information, whether it is tangible or intangible. Executive further agrees not to use any such confidential information or trade secrets to his/her personal benefit or for the benefit of any third party.
Executive further acknowledges that for purposes of interpreting Articles III and IV of this Employment Agreement, covenants and obligations of Executive with respect to the Company apply equally with respect to its affiliates. Executive also acknowledges that Property belongs to the Company and agrees to return to the Company all such information and Property which is tangible upon the Executives Separation of Service.
-11-
Executive acknowledges that the use, misappropriation, or disclosure of the Property would constitute a breach of trust and could cause irreparable injury to the Company, and it is essential to the protection of the Companys good will and to the maintenance of the Companys competitive position that the Property be kept secret and that Executive not disclose the Property to others or use the property to Executives own advantage or the advantage of others.
Executive further recognizes and understands that his Services at the Company may include the preparation of materials, including written or graphic materials, and that any such materials conceived or written by him shall be done as work made for hire as defined and used in the Copyright Act of 1976, 17 USC Section 1 et seq . In the event of publication of such materials, Executive understands that since the work is a work made for hire, the Company will solely retain and own all rights in said materials, including right of copyright, and that the Company may, at its discretion, on a case-by-case basis, grant Executive by-line credit on such materials as the Company may deem appropriate.
ARTICLE IV
EXECUTIVES COVENANTS AND AGREEMENTS
4.01. Non-Disclosure of Property . Executive agrees to hold and safeguard the Property in trust for the Company, its successors and assigns and agrees that he shall not, without the prior written consent of the Company, misappropriate or disclose or make available to anyone for use outside the Companys organization at any time, either during his employment with the Company or subsequent to the termination of his employment with the Company for any reason, including without limitation Separation of Service by the Company for cause or without cause, any confidential information that constitutes trade secrets, whether or not developed by Executive, except as required in the performance of Executives Services to the Company or as otherwise required by law or legal process. Executive and the Company agree that Executives obligations under the above non-disclosure provision as it relates to confidential information that does not constitute trade secrets shall apply for a period of three (3) years following the Separation of Service of the Executive.
4.02. Disclosure of Works and Inventions/Assignment of Patents and Other Rights . (a) Executive shall disclose promptly to the Company or its nominee any and all works, inventions, discoveries and improvements authored, conceived or made by Executive during the period of employment and related to the business or activities of the Company, and hereby assigns and agrees to assign all his interest therein to the Company or its nominee. Whenever requested to do so by the Company, Executive shall execute any and all applications, assignments or other instruments which the Company shall deem necessary to apply for and obtain Letters Patent or Copyrights of the United States or any foreign country or to otherwise protect the Companys interest therein. Such obligations shall continue beyond the termination of employment with respect to works, inventions, discoveries and improvements authored, conceived or made by Executive during the period of employment, and shall be binding upon Executives assigns, executors, administrators and other legal representatives.
(b) Executive agrees that in the event of publication by Executive of written or graphic materials the Company will retain and own all rights in said materials, including right of copyright.
-12-
4.03. Services . During the Term of this Agreement, Executive agrees to devote his best efforts full time to the performance of his Services for the Company, to give proper time and attention to furthering the Companys business, and to comply in all material respects with all rules, regulations and instruments established or issued by the Company and made known to Executive. Executive further agrees that during the Term of this Agreement, Executive shall not, directly or indirectly, engage in any business which would detract from Executives ability to apply his best efforts to the performance of his Services hereunder. Executive also agrees that he shall not usurp any corporate opportunities of the Company during the Term of this Agreement. The Services set forth in this Section 4.03 shall apply during the Term of this Agreement.
4.04. Return of Materials . Upon the Executives Separation of Service with the Company for any reason, including without limitation Separation of Service by the Company for cause or without cause, Executive shall promptly deliver to the Company all correspondence, drawings, blue-prints, manuals, letters, notes, notebooks, reports, flow-charts, programs, proposals and any documents concerning the Companys customers or concerning products or processes used by the Company and, without limiting the foregoing, will promptly deliver to the Company any and all other documents or materials containing or constituting Property.
4.05. Restrictions on Competition . Executive acknowledges that as Executive Vice President and Chief Operating Officer he will be a high impact person in the Companys business who is in possession of selective and specialized skills, learning abilities, supplier and customer contacts, and supplier and customer information as a result of his relationship with the Company, and agrees that the Company has a substantial business interest in the covenant described below. Executive further acknowledges that he is involved at the highest level of the Company in the development of strategy and products, and is responsible for new product development nationally and internationally, has significant and regular contact with customers and suppliers of the Company, and that he has access to and responsibility for trade secret and confidential information pertaining to the business of the Company, its products and plans. In recognition of that status, Executive covenants and agrees that during the Term plus a period of two years (or such longer period, not in excess of three years, to the extent Separation of Service payments are paid to Executive pursuant to Sections 2.04, 2.05 or 2.06 in an amount representing a period in excess of two years) following Executives Separation of Service, including without limitation Separation of Service by the Company for cause or without cause (excepting a Separation of Service pursuant to Section 2.01), Executive shall not, in the United States of America engage, directly or indirectly, whether as principal or as agent, officer, director, employee, consultant, shareholder (other than as a shareholder owning up to 5% of the outstanding stock of any company whose stock is publicly traded and listed on a national securities exchange or included in NASDAQ), alone or in association with any other person, corporation or other entity, in any Competing Business; provided , however , that with respect to a Separation of Service occurring during the Change of Control Protection Period, the foregoing restriction shall apply for a period equal to one half of the applicable period otherwise prescribed by this sentence. For purposes of this Agreement, the term Competing Business shall mean and include any person, corporation or other entity which develops, manufactures, sells, markets or attempts to develop, manufacture, sell or market any product or services which are the same as or similar to the Products and services sold by the Company at any time and from time to time during the last two years prior to the Executives Separation of Service hereunder; provided , however , that for purposes of determining what constitutes a Competing Business there shall not be included (x) any product or service of any entity which product or service Executive determines is not material to the business or prospects of the Company and which product or service the
-13-
Companys Board, having been requested to do so by Executive, also so determines; the parties agree that any product which has been marketed in the United States for five years and has not achieved a five percent revenue level for the Company is not material for purposes of this provision or (y) any product or service of any entity so long as the Executive and such entity can demonstrate to the reasonable satisfaction of the Company that Executive is and will continue to be effectively isolated from, and not participate in the development, manufacture, sale or marketing of, such product or service, but only so long as Executive is effectively so isolated and does not so participate. To trigger this provision, the Executive and entity must perform the following: (i) the Executive must provide the Company with a letter pledging that he will abide by this Agreement; provided , however , that this requirement shall not apply in the event of a Separation of Service during the Change of Control Protection Period, and (ii) the prospective/new employer must provide a letter acknowledging that it is aware of the Executives obligations hereunder; provided , however , that this requirement shall not apply in the event of a Separation of Service during the Change of Control Protection Period. The letter also must contain a pledge by the new/prospective employer that it will abide by those obligations. In the event the Term expires before Executive obtains the age of 65 and because the Company has elected not to further extend the Term pursuant to Section 1.02, then the provisions of this Section 4.05 and Sections 4.06 and 4.07 shall not be applicable after the conclusion of the Term unless the Company advises Executive at least six months prior to conclusion of the Term that it will continue to pay the Base Salary in effect at conclusion of the Term for such two-year period or such shorter portion thereof as the Company may specify (which specification shall shorten such two-year period accordingly) and the Company pays such amounts during such two-year or shorter period in equal bi-weekly installments; provided , however , that payment of any such amount will not begin until six (6) months after the expiration of the Term and any payment for this six-month waiting period will be paid in a lump sum as part of the first payment immediately after the six-month period has passed and thereafter any payments due will be paid bi-weekly in accordance with the Companys then current payroll practice; and provided further, however, that, in the event that Executive receives payments contemplated by Section 2.05 as a result of the Companys failure to extend the Term in a Change in Control Protection Period as set forth in Section 2.04(a)(x), then Sections 4.05, 4.06 and 4.07 shall apply for the following time period(s) without any further payment: Section 4.05 (eighteen months), Section 4.06 (one year) and Section 4.07 (one year). For the avoidance of doubt, (1) if the Company elects to continue to pay Executives Base Salary as contemplated by the immediately preceding sentence so that Sections 4.05, 4.06 and 4.07 will apply following the Companys failure to extend the Term, such payments shall be in addition to any other payments contemplated by this Agreement, and (2) the Company may only make such election if Section 4.05, 4.06 and 4.07 would not otherwise not apply.
4.06. Non-Solicitation of Customers and Suppliers . Executive agrees that during the Term he shall not, directly or indirectly, solicit the trade of, or trade with, any customer, prospective customer, supplier, or prospective supplier of the Company for any business purpose other than for the benefit of the Company, with respect to any products competitive with those of the Company. Executive further agrees that for two years following Executives Separation of Service with the Company, including without limitation Separation of Service by the Company for cause or without cause, Executive shall not, directly or indirectly, solicit the trade of, or trade with, any customers or suppliers of the Company with respect to any products competitive with those of the Company; provided , however , that with respect to a Separation of Service occurring during the Change of Control Protection Period, the foregoing restriction shall apply for a period of one year following the Executives Separation of Service with the Company (in lieu of the longer period described at the beginning of this sentence).
-14-
4.07. Non-Solicitation of Employees . Executive agrees that, during the Term and for two years following Executives Separation of Service with the Company, including without limitation Separation of Service by the Company with cause or without cause, Executive shall not, directly or indirectly, solicit or induce, or attempt to solicit or induce, any employee of the Company to leave the Company for any reason whatsoever, or hire any employee of the Company without permission from the Company; provided , however , that with respect to a Separation of Service occurring during the Change of Control Protection Period, the foregoing restriction shall apply for a period of one year following the Executives Separation of Service with the Company (in lieu of the longer period described at the beginning of this sentence).
ARTICLE V
EXECUTIVES REPRESENTATIONS AND WARRANTIES
5.01. No Prior Agreements . Executive represents and warrants that he is not a party to or otherwise subject to or bound by the terms of any contract, agreement or understanding which in any manner would limit or otherwise affect his ability perform his obligations hereunder, including without limitation any contract, agreement or understanding containing terms and provisions similar in any manner to those contained in Article IV hereof. Executive further represents and warrants that his employment with the Company will not require him to disclose or use any confidential information belonging to prior employers or other persons or entities other than Healthdyne.
5.02. Executives Abilities . Executive acknowledges that it would cause the Company serious and irreparable injury and cost if Executive were to use his ability and knowledge in competition with the Company or to otherwise breach the obligations contained in Article IV.
5.03. Remedies . In the event of a breach by Executive of the terms of this Agreement, the Company shall be entitled, if it shall so elect, to institute legal proceedings to obtain damages for any such breach, or to enforce the specific performance of this Agreement by Executive and to enjoin Executive from any further violation of this Agreement and to exercise such remedies cumulatively or in conjunction with all other rights and remedies provided by law. Executive acknowledges, however, that the remedies at law for any breach by him of the provisions of this Agreement may be inadequate and that the Company shall be entitled to injunctive relief against him in the event of any breach. During the Change of Control Protection Period, in no event shall an asserted violation of the provisions of Article IV constitute a basis for deferring or withholding any amounts otherwise payable to Executive under this Agreement.
ARTICLE VI
MISCELLANEOUS
6.01. PNC Loan and Related Provisions . (a) The parties hereby acknowledge that Executive has borrowed $300,000 from PNC Bank, National Association to Executive (the PNC Loan ).
(b) The Company agrees during the Term and the Extended Employment Period to reimburse Executive on a monthly basis for, or advance to Executive, an amount equal to the interest payable by Executive on the PNC Loan. Payment of such reimbursements or advance shall be made no later than the end of Executives taxable year following the taxable year in which the expense is incurred. Amounts eligible for
-15-
reimbursement or advance in one taxable year shall not affect the amount eligible for reimbursement or advance to be provided in any other taxable year. The right to any such reimbursement or advance hereunder shall not be subject to liquidation or exchange for any other benefit.
(c) For each calendar year during the Term of Employment Agreement and the Extended Employment Period, the Company shall gross-up one time Executives income to account for any additional federal and state income tax payable by Executive as a result of the Companys reimbursement of Executive for interest payable on the PNC Loan. Such gross-up shall be paid at the maximum applicable rate on an annual basis at such time as Executive has determined his tax liability with respect to such interest reimbursement for the prior year, however, in no event will any gross-up payment be made later than the end of any taxable year of Executive in which the related taxes are remitted to the taxing authority.
6.02. Authorization to Modify Restrictions . It is the intention of the parties that the provisions of Article IV hereof shall be enforceable to the fullest extent permissible under applicable law, but that the unenforceability (or modification to conform to such law) of any provision or provisions hereof shall not render unenforceable, or impair, the remainder thereof. If any provision or provisions hereof shall be deemed invalid or unenforceable, either in whole or in part, this Agreement shall be deemed amended to delete or modify, as necessary, the offending provision or provisions and to alter the bounds thereof in order to render it valid and enforceable.
6.03. Entire Agreement . This Agreement represents the entire agreement of the parties with respect to the employment of Executive by the Company and may be amended only by a writing signed by each of them. For the avoidance of doubt, the Supplemental Employment Agreement, dated as of November 11, 1997, by and between Executive and the Company, shall terminate by virtue of the execution of this Agreement and shall no longer have any effect.
6.04. Governing Law . This Agreement shall be governed by and construed in accordance with the laws of the Commonwealth of Pennsylvania.
6.05. Consent to Jurisdiction; Venue . Executive hereby irrevocably submits to the personal jurisdiction of the United States District Court for the Western District of Pennsylvania or the Court of Common Pleas of Allegheny County, Pennsylvania in any action or proceeding arising out of or relating to this Agreement that cannot be finally resolved by arbitration pursuant to Section 6.06 hereof (and for enforcement of any such arbitration decision), and Executive hereby irrevocably agrees that all claims in respect of any such action or proceeding may be heard and determined in either such court. Executive hereby irrevocably waives any objection which he now or hereafter may have to the laying of venue of any action or proceeding arising out of or relating to this Agreement brought in the United States District Court for the Western District of Pennsylvania or the Court of Common Pleas of Allegheny County, Pennsylvania and any objection on the ground that any such action or proceeding in either of such Courts has been brought in an inconvenient forum. Nothing in this Section 6.05 shall affect the right of the Company to bring any action or proceeding against Executive or his property in the courts of other jurisdictions where the Executive resides or has his principal place of business or where such property is located. The parties agree and acknowledge that a breach by the Company of its obligations under this Agreement will result in significant damages to Executive. Accordingly, in order to provide certainty with respect to Executives ability to receive the benefit of his bargain,
-16-
Executive, in the event of a breach by the Company of its covenants, representations and warranties in this Agreement, shall be entitled, in addition to any other remedies that he may have, to require specific performance of the covenants, representations and warranties of this Agreement.
6.06. Arbitration . Unless the party seeking relief is seeking relief not available through arbitration hereunder (see Section 6.05), any dispute related to this Agreement shall be referred to arbitration by three arbitrators selected from a list of arbitrators affiliated with American Arbitration Association ( AAA ) who are familiar with executive employment matters, with one arbitrator being selected by the Company, one arbitrator being selected by Executive, and the third arbitrator being selected jointly by the two arbitrators selected by the Company and by Executive. The decision of a majority of the arbitrators shall constitute the arbitral decision. The arbitration hereunder, shall be conducted pursuant to the rules and procedures of AAA then in effect and otherwise in such manner as the arbitrator or arbitrators shall determine and shall be conducted in Pittsburgh, Pennsylvania. All parties shall cooperate with each other to expedite the arbitration process as much as possible so that the dispute can be resolved as quickly as possible and with as little cost as possible. The arbitral decision shall be final, binding and conclusive on the parties and may be entered, if necessary, in a court of competent jurisdiction with the same force and effect as a final and binding judgment. The arbitrators shall further be authorized to allocate or assess the costs of arbitration, including attorneys fees, between the respective parties. If the arbitrators do not award costs and expenses, then each party shall bear its own costs and expenses, including attorneys fees, and the cost of the arbitration shall be paid by the party whose position in the arbitration does not prevail.
6.07. Agreement Binding . The obligations of Executive under this Agreement that continue after the Separation of Service with the Company for any reason, with or without cause, and shall be binding on his heirs, executors, legal representatives and assigns and shall inure to the benefit of any successors and assigns of the Company.
6.08. Counterparts, Section Headings . This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original, but all of which together shall constitute one and the same instrument. The section headings of this Agreement are for convenience of reference only and shall not affect the construction or interpretation of any of the provisions hereof.
6.09. Notices . All notices, requests, demands and other communications hereunder shall be in writing and shall be deemed to have been duly given if (a) hand delivered or (b) mailed, registered mail, first class postage paid, return receipt requested, or (c) sent via overnight delivery service or courier, delivery acknowledgment requested, or (d) via any other delivery service with proof of delivery:
if to the Company:
Respironics, Inc.
1010 Murry Ridge Lane
Murrysville, PA 15668
Attn: President
if to Executive, at the address set forth on the signature page hereof or to such other address or to such other person as either party hereto shall have last designated by notice to the other party.
-17-
6.10. Section 409A . Within the time period permitted by the applicable Treasury Regulations, the parties may agree to modify the Agreement, in the least restrictive manner necessary and without any diminution in the value of the payments to, or protections for, Executive, in order to cause the provisions of the Agreement to comply with the requirements of Section 409A of the Code, so as to avoid the imposition of taxes and penalties on Executive pursuant to Section 409A of the Code. In the event that the Executive requests in writing that the Company agree to modify provisions of this Agreement in a manner that will not result in any increase in the cost to the Company (other than administrative or legal costs) in order to cause the provisions to comply with the requirements of Section 409A of the Code, the Company agrees in good faith to make such amendment.
6.11. Attorneys Fees . The Company agrees to pay as incurred (within 10 days following the Companys receipt of an invoice from Executive), at any time from the date of this Agreement through Executives remaining lifetime or, if longer, through the 20th anniversary of the Effective Date, to the full extent permitted by law, all legal fees and expenses that Executive may reasonably incur as a result of any contest (regardless of the outcome thereof) by the Company, Executive or others of the validity or enforceability of, or liability under, any provision of this Agreement or any guarantee of performance thereof (including as a result of any contest by Executive about the amount of any payment pursuant to this Agreement) arising in connection with a Change of Control, Separation of Service or termination of employment during the Change of Control Protection Period, plus, in each case, interest on any delayed payment at the applicable federal rate provided for in Section 7872(f)(2)(A) of the Code, provided, that Executive shall have submitted an invoice for such fees and expenses at least 10 days before the end of the calendar year next following the calendar year in which such fees and expenses were incurred.
6.12. Successor to the Company . The Company will require any successor or assign (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business and/or assets of the Company, by agreement in form and substance satisfactory to the Executive, expressly, absolutely and unconditionally to assume and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform it if no such succession or assignment had taken place. Any failure of the Company to obtain such agreement prior to the effectiveness of any such succession or assignment shall be a material breach of this Agreement and shall entitle the Executive to terminate Executives Services and to receive the payments and other benefits set forth in Section 2.05 and Section 2.08 as if Executives Services had been terminated without cause during the Change of Control Protection Period. As used in this Agreement, Company shall mean the Company as hereinbefore defined and any successor or assign to its business and/or assets as aforesaid.
-18-
Executive acknowledges that he has read and understands the foregoing provisions and that such provisions are reasonable and enforceable. IN WITNESS WHEREOF, the parties hereto have executed this Agreement or caused this Agreement to be executed the day and year first above written.
|
/s/ CRAIG REYNOLDS |
||
|
Address: |
1046 MIDDLEBROOK WAY NW KENNESAW, GA 30152 |
|
| RESPIRONICS, INC. | ||
|
By: |
/s/ William R. Wilson |
|
|
Title: |
Chief Human Resources Officer | |
-19-
Exhibit 31.1
Respironics, Inc. and Subsidiaries
Three and six months ended December 31, 2007
SECTION 302 CERTIFICATIONS
I, John L. Miclot, certify that:
| 1. | I have reviewed this quarterly report on Form 10-Q of Respironics, Inc.; |
| 2. | Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report; |
| 3. | Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report; |
| 4. | The registrants other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
| (a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared; |
| (b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
| (c) | Evaluated the effectiveness of the registrants disclosure controls and procedures and presented in this quarterly report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; |
| (d) | Disclosed in this quarterly report any change in the registrants internal control over financial reporting that occurred during the registrants most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrants internal control over financial reporting; |
| 5. | The registrants other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrants auditors and the audit committee of registrants board of directors (or persons performing the equivalent functions): |
| (a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrants ability to record, process, summarize and report financial information; and |
| (b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrants internal control over financial reporting. |
Date: February 11, 2008
|
/ S / J OHN L. M ICLOT |
||
| Name: | John L. Miclot | |
| Title: | President and Chief Executive Officer |
27
Exhibit 31.2
Respironics, Inc. and Subsidiaries
Three and six months ended December 31, 2007
I, Daniel J. Bevevino, certify that:
| 1. | I have reviewed this quarterly report on Form 10-Q of Respironics, Inc.; |
| 2. | Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report; |
| 3. | Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report; |
| 4. | The registrants other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
| (a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared; |
| (b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
| (c) | Evaluated the effectiveness of the registrants disclosure controls and procedures and presented in this quarterly report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; |
| (d) | Disclosed in this quarterly report any change in the registrants internal control over financial reporting that occurred during the registrants most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrants internal control over financial reporting; |
| 5. | The registrants other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrants auditors and the audit committee of registrants board of directors (or persons performing the equivalent functions): |
| (a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrants ability to record, process, summarize and report financial information; and |
| (b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrants internal control over financial reporting. |
Date: February 11, 2008
|
/ S / D ANIEL J. B EVEVINO |
||
| Name: | Daniel J. Bevevino | |
| Title: | Vice President and Chief Financial Officer |
28
Exhibit 32
Respironics, Inc. and Subsidiaries
Three and six months ended December 31, 2007
SECTION 906 CERTIFICATIONS
Pursuant to 18 U.S.C. § 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officers of Respironics, Inc. (the Company), hereby certify that the Companys Quarterly Report on Form 10-Q for the three-month and six-month periods ended December 31, 2007 (the Report) fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Dated: February 11, 2008
|
/ S / J OHN L. M ICLOT |
||
| Name: | John L. Miclot | |
| Title: | President and Chief Executive Officer | |
|
/ S / D ANIEL J. B EVEVINO |
||
| Name: | Daniel J. Bevevino | |
| Title: | Vice President and Chief Financial Officer | |
This certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as part of the Report or as a separate disclosure document.
A signed original of the written statement required by Section 906 has been provided to Respironics, Inc. and will be retained by Respironics, Inc. and furnished to the SEC or its staff upon request.
29